WO2014116132A1 - Biomaterial comprising poly(trimethylene carbonate-co-e-caprolactone) for promoting axonall growth and neuronal regeneration - Google Patents
Biomaterial comprising poly(trimethylene carbonate-co-e-caprolactone) for promoting axonall growth and neuronal regeneration Download PDFInfo
- Publication number
- WO2014116132A1 WO2014116132A1 PCT/PT2014/000006 PT2014000006W WO2014116132A1 WO 2014116132 A1 WO2014116132 A1 WO 2014116132A1 PT 2014000006 W PT2014000006 W PT 2014000006W WO 2014116132 A1 WO2014116132 A1 WO 2014116132A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biomaterial
- tmc
- use according
- caprolactone
- trimethylene carbonate
- Prior art date
Links
- 239000012620 biological material Substances 0.000 title claims abstract description 69
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 title claims abstract description 18
- 230000009689 neuronal regeneration Effects 0.000 title claims description 16
- 230000001737 promoting effect Effects 0.000 title claims description 14
- 230000012010 growth Effects 0.000 title abstract description 10
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 46
- 230000006378 damage Effects 0.000 claims abstract description 32
- -1 poly(trimethylene carbonate) Polymers 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 17
- 208000014674 injury Diseases 0.000 claims abstract description 13
- 210000000278 spinal cord Anatomy 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 5
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 claims description 44
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 36
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 25
- 210000005036 nerve Anatomy 0.000 claims description 12
- 208000020431 spinal cord injury Diseases 0.000 claims description 9
- 230000021164 cell adhesion Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000000474 Poliomyelitis Diseases 0.000 claims description 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
- 102000006386 Myelin Proteins Human genes 0.000 abstract description 38
- 108010083674 Myelin Proteins Proteins 0.000 abstract description 38
- 210000005012 myelin Anatomy 0.000 abstract description 37
- 239000000463 material Substances 0.000 abstract description 32
- 210000002569 neuron Anatomy 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 31
- 210000003618 cortical neuron Anatomy 0.000 abstract description 30
- 230000003376 axonal effect Effects 0.000 abstract description 29
- 230000008929 regeneration Effects 0.000 abstract description 27
- 238000011069 regeneration method Methods 0.000 abstract description 27
- 229920000642 polymer Polymers 0.000 abstract description 19
- 239000011521 glass Substances 0.000 abstract description 18
- 230000005764 inhibitory process Effects 0.000 abstract description 18
- 239000000758 substrate Substances 0.000 abstract description 17
- 206010061431 Glial scar Diseases 0.000 abstract description 9
- 206010018341 Gliosis Diseases 0.000 abstract description 9
- 208000027418 Wounds and injury Diseases 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000008569 process Effects 0.000 abstract description 7
- 238000013459 approach Methods 0.000 abstract description 6
- 230000001404 mediated effect Effects 0.000 abstract description 6
- 230000003902 lesion Effects 0.000 abstract description 5
- 230000019491 signal transduction Effects 0.000 abstract description 5
- 229920000166 polytrimethylene carbonate Polymers 0.000 abstract description 4
- 230000001172 regenerating effect Effects 0.000 abstract description 4
- 102100024425 Dihydropyrimidinase-related protein 3 Human genes 0.000 abstract description 3
- 108050002650 Dihydropyrimidinase-related protein 3 Proteins 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 230000018109 developmental process Effects 0.000 abstract description 2
- 238000011835 investigation Methods 0.000 abstract description 2
- 108091007911 GSKs Proteins 0.000 abstract 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 46
- 210000002241 neurite Anatomy 0.000 description 46
- 229920001577 copolymer Polymers 0.000 description 26
- 230000001537 neural effect Effects 0.000 description 20
- 239000010408 film Substances 0.000 description 17
- 238000006366 phosphorylation reaction Methods 0.000 description 16
- 230000026731 phosphorylation Effects 0.000 description 15
- 230000014511 neuron projection development Effects 0.000 description 14
- 238000006116 polymerization reaction Methods 0.000 description 14
- 102000001267 GSK3 Human genes 0.000 description 12
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000010287 polarization Effects 0.000 description 8
- HUDSYNWJCPDHLL-CJLVFECKSA-N [(E)-[2-(6-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate Chemical compound CC(=O)O\N=C1\C(=Nc2ccccc12)c1c(O)[nH]c2cc(Br)ccc12 HUDSYNWJCPDHLL-CJLVFECKSA-N 0.000 description 7
- 210000003050 axon Anatomy 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 5
- 238000003365 immunocytochemistry Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000004630 atomic force microscopy Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000006059 cover glass Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000007373 indentation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 230000007514 neuronal growth Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 101150111584 RHOA gene Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 3
- 238000012876 topography Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- 229940035658 visco-gel Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 239000012122 aqueous mounting media Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000009038 pharmacological inhibition Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 238000012667 polymer degradation Methods 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241001082241 Lythrum hyssopifolia Species 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 1
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002502 anti-myelin effect Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000003619 fibrillary effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 102000021160 microtubule binding proteins Human genes 0.000 description 1
- 108091011150 microtubule binding proteins Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000023362 neuron cell-cell adhesion Effects 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000035771 neuroregeneration Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- NREVZTYRXVBFAQ-UHFFFAOYSA-N propan-2-ol;yttrium Chemical compound [Y].CC(C)O.CC(C)O.CC(C)O NREVZTYRXVBFAQ-UHFFFAOYSA-N 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 102000000568 rho-Associated Kinases Human genes 0.000 description 1
- 108010041788 rho-Associated Kinases Proteins 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XMUSXQUBKOIUQO-UHFFFAOYSA-J vondocarb Chemical compound [Mn+2].[Zn+2].[S-]C(=S)NCCNC([S-])=S.[S-]C(=S)NCCNC([S-])=S.C1=CC=C2NC(NC(=O)OC)=NC2=C1 XMUSXQUBKOIUQO-UHFFFAOYSA-J 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a biomaterial for use in medicine, in particular for promoting neuronal growth in the central nervous system, wherein the biomaterial comprises poly(trimethylene carbonate-co-8-caprolactone) (P(TMC-CL)).
- P(TMC-CL) poly(trimethylene carbonate-co-8-caprolactone)
- This biomaterial can be used in the regeneration of neurons in the central nervous system (CNS), such as the spinal cord.
- BBB blood-brain barrier
- Poly(1ximethylene carbonate-co-s-caprolactone) (P(TMC-CL)) copolymers or the parental trimethylene carbonate (TMC) homopolymer are very flexible and tough materials that can be processed into highly porous three dimensional structures with degradation rates that can be modulated by adjusting the co-monomer content [20, 21]. These materials have been shown to be biocompatible [21-23] and have been previously explored for peripheral nerve regeneration conduits [20, 23-26]. Additionally, polymer degradation occurred with minimum swelling of the material [23], which is also an essential feature to prevent nerve compression that could compromise regeneration.
- P(TMC-CL) copolymers have been previously explored for peripheral nerve regeneration, regeneration of nerves in the CNS is hampered by the inhibitory environment formed by the glial scar, largely constituted by myelin debris. For example, it has been shown that many materials, which have shown an effect in the periphery, do not promote nerve regeneration in the CNS. Furthermore, there is no material that has been found to be able to promote axonal elongation and neuronal polarization, even in the absence of myelin (an inhibitory substrate). Therefore, there would be no expectation that P(TMC-CL) copolymers would be able promote neuronal growth in the CNS, in particular, axonal elongation and neuronal polarization.
- the present invention provides a biomaterial for use in medicine, namely for promoting neuronal regeneration in the CNS, wherein the biomaterial comprises poly(trimethylene carbonate-co-s-caprolactone) (P(TMC-CL)).
- P(TMC-CL) poly(trimethylene carbonate-co-s-caprolactone)
- the copolymer poly(trimethylene carbonate-co-e- caprolactone) is able to promote neuronal regeneration, in particular, neuronal polarization and axonal elongation, in the CNS, even under inhibitory conditions. This is especially surprising as polymers of the two constituents, i.e. poly(trimethylene carbonate) and poly(8-caprolactone) do not promote this effect on their own.
- the biomaterial can be used to treat conditions in which neuronal regeneration of the CNS is required.
- the CNS is defined as the brain and the spinal cord of a subject.
- the CNS does not include the sciatic nerves.
- the biomaterial can be used to treat damage to the CNS.
- the invention provides a biomaterial for use in treating damage to the CNS, wherein the biomaterial comprises poly(trimethylene carbonate-co-e-caprolactone) (P(TMC-CL)).
- P(TMC-CL) poly(trimethylene carbonate-co-e-caprolactone)
- This damage may occur as a result of a number of different causes.
- the damage may occur due to a disease, which causes damage to the CNS, or injury.
- damage to the CNS may occur as a result of: trauma, e.g. a spinal cord injury (SCI); an infection such as poliomyelitis; neurodegeneration such as amyotrophic lateral sclerosis; a tumour; an autoimmune and/or inflammatory disease such as multiple sclerosis; or spinal stroke.
- the damage to the CNS is caused by disease, the biomaterial causes regeneration of nerves in the CNS rather than treating the underlying cause of the damage.
- the biomaterial can be used to treat injury or trauma to the CNS.
- the biomaterial can be used to treat spinal cord injury. This typically happens as a result of damage to the spinal cord of a subject.
- Poly(trimethylene carbonate-co-e-caprolactone) is a copolymer formed from the monomers trimethylene carbonate and ⁇ -caprolactone.
- This copolymer can be formed in any suitable way.
- polymerisation may be carried out using ring-opening polymerization. This may be done in an inert atmosphere such as an argon atmosphere or in solution.
- the polymerization reaction is carried out in an inert atmosphere.
- a catalyst may be used such as stannous octoate or yttrium isopropoxide.
- stannous octoate is used as a catalyst.
- the polymerization reaction may be carried out for a period of between 1 and 40 days depending on the temperature of polymerisation and the size of polymer required.
- the polymerization reaction may be carried out for a period of between 1 and 5 days. In some embodiments, the polymerization reaction is carried out for between 2 and 4 days. In particular embodiments, the polymerization reaction is carried out for 3 days.
- the polymerization reaction may be carried out at between about 60°C and about 200°C or between about 100°C and about 160°C. In some embodiments, the polymerisation reaction is carried out at between about 110°C and about 150°C. In further embodiments, the polymerisation reaction may be carried out at between about 120°C and about 140°C.
- the polymerisation reaction may be carried out at about 130°C, e.g. 130°C ⁇ 2°C.
- the polymerization reaction is carried out for between 2 and 4 days at between about 100°C and about 160°C. In some embodiments, the polymerization reaction is carried out for 3 days at between about 120°C and about 140°C such as about 130°C, e.g. 130°C ⁇ 2°C.
- the poly(trimethylene carbonate-co-E-caprolactone) contains trimethylene carbonate and ⁇ - caprolactone as monomers.
- the ratio of these monomers should be such that the polymer has the required physical properties to cause neuronal regeneration in the CNS.
- the molar ratio of trimethylene carbonate to ⁇ -caprolactone may be between about 1 :20 and about 1:3, respectively.
- the molar ratio of trimethylene carbonate to ⁇ - caprolactone may be between about 1:1 and about 1:3.
- the molar ratio of trimethylene carbonate to ⁇ -caprolactone may be between about 1:17 and about 1:3.
- the molar ratio of trimethylene carbonate to ⁇ -caprolactone may be between about 1:15 and about 1:3. In particular embodiments, the molar ratio of trimethylene carbonate to ⁇ -caprolactone may be between about 1:20 and about 1:4. In certain embodiments, the molar ratio of trimethylene carbonate to ⁇ -caprolactone may be between about 1:15 and about 1:5. The molar ratio of trimethylene carbonate to ⁇ -caprolactone may be between about 1:10 and about 1 :6. Further, the molar ratio of trimethylene carbonate to ⁇ -caprolactone may be between about 1 :9 and about 1 :7. The molar ratio of trimethylene carbonate to ⁇ -caprolactone may be about 1:8.
- the molar ratio of trimethylene carbonate to ⁇ -caprolactone may be between about 5:95 and about 25:75, respectively. In other embodiments, the molar ratio of trimethylene carbonate to ⁇ -caprolactone may be between about 5:95 and about 23:77. In further embodiments, the molar ratio of trimethylene carbonate to ⁇ -caprolactone may be between about 5:95 and about 21:79. In particular embodiments, the molar ratio of trimethylene carbonate to ⁇ -caprolactone may be between about 5:95 and about 19:81. In certain embodiments, the molar ratio of trimethylene carbonate to ⁇ -caprolactone may be between about 5:95 and about 17:83.
- the molar ratio of trimethylene carbonate to ⁇ -caprolactone may be between about 7:93 and about 15:85. Further, the molar ratio of trimethylene carbonate to ⁇ - caprolactone may be between about 9:91 and about 13:87. Furthermore, the molar ratio of trimethylene carbonate to ⁇ -caprolactone may be between about 10:90 and about 12:88. The molar ratio of trimethylene carbonate to ⁇ -caprolactone may be about 11 :89.
- the trimethylene carbonate and the ⁇ -caprolactone should be polymerised to an appropriate degree to give a polymer with the required characteristics.
- the degree of polymerisation can be measured using the number average molecular weight (Mn).
- the copolymer may have a number average molecular weight of at least about 0.2 x 10 5 .
- the copolymer may have a number average molecular weight of less than about 2 x 10 5 . In some embodiments, the copolymer has a number average molecular weight of less than about 1.5 x 10 5 .
- the copolymer may have a number average molecular weight of less than about 1 x 10 5 . In further embodiments, the copolymer may have a number average molecular weight of less than about 0.75 x 10 s . In other embodiments, the copolymer may have a number average molecular weight of less than about 0.5 x 10 s .
- the copolymer has a number average molecular weight of at least about 0.2 x 10 5 and less than about 1 x 10 5 .
- the copolymer may have a number average molecular weight of about 0.37 x 10 5 .
- the copolymer may have a stiffness of between about 200 N/m and about 400 N/m.
- the copolymer may have a stiffness of about 312 N/m.
- the copolymer may have a hardness of between about 1 x 10 6 N/m 2 and about 6 x 10 6 N/m 2 .
- the copolymer has a hardness of between about 2 x 10 6 N/m 2 and about 5 x 10 6 N/m 2 .
- the copolymer has a hardness of between about 3 x 10 6 N/m 2 and about 4 x 10 6 N/m 2 .
- the copolymer may have a hardness of about 3.32 x 10 6 N/m 2 .
- the copolymer may have a roughness of between about 10 nm and about 50 nm.
- the copolymer may have a roughness of about 24 nm.
- the poly(trimethylene carbonate-co-e-caprolactone) may be coated with a molecule that promotes cell adhesion to the polymer.
- This molecule may be any suitable molecule such as fibronectin, laminins (e.g. laminin-111), collagen (e.g. collagen type I), poly(ethylene imine) or synthetic oligopeptides or polypeptides (e.g. poly(L-lysine) (PLL)).
- the poly(trimethylene carbonate-co-e-caprolactone) is coated with laminin-111 or PLL.
- the poly(trimethylene carbonate-co-e-caprolactone) is coated with PLL.
- the biomaterial and/or the P(TMC-CL) may be in any suitable form for use in promoting neuronal regeneration.
- the biomaterial and/or the P(TMC-CL) may be in the form of a scaffold, e.g. a three dimensional scaffold.
- the scaffold may be porous.
- the biomaterial may be in the form of a nerve guide, e.g. with a hollow tubular shape (cylindrical). Such a nerve guide will serve as a conduit for axonal growth.
- the conduit may be constituted by an assembly of smaller diameter nerve guides.
- the biomaterial can also be in the form of fibres, for example, prepared from extrusion, elecfrospinning or spun from solution.
- the biomaterial may be in the form of films, beads or microspheres.
- the biomaterial may be in the form of a patch. These can be implanted into the brain or spinal cord for promoting neuronal regeneration.
- the films can have topographical features, like aligned channels or poles that can be obtained by microfabrication techniques.
- the biomaterial and/or the P(TMC-CL) may be plasma treated to alter surface morphology and/or chemistry.
- the biomaterial and/or the P(TMC-CL) may comprise one or more active pharmaceutical ingredients.
- the pharmaceutical ingredient may be an active agent such as ibuprofen, rolipram or diclofenac.
- the present invention also provides the use of a biomaterial in the preparation of a composition for promoting neuronal regeneration in the CNS, wherein the biomaterial comprises poly(trimethylene carbonate-co-s-caprolactone) (P(TMC-CL)).
- the biomaterial comprises poly(trimethylene carbonate-co-s-caprolactone) (P(TMC-CL)).
- the invention provides the use of a biomaterial in the preparation of a composition for treating damage to the CNS, wherein the biomaterial comprises poly(trimethylene carbonate-co- ⁇ -caprolactone) (P(TMC-CL)).
- the biomaterial comprises poly(trimethylene carbonate-co- ⁇ -caprolactone) (P(TMC-CL)).
- the present invention provides a method of promoting neuronal regeneration in the CNS of a subject, the method comprising administering a biomaterial comprising poly(rrimethylene carbonate-co-s-caprolactone) to a site of damage in the CNS of the subject.
- the biomaterial may be administered in any suitable way. It may be implanted or injected. Generally, the biomaterial will be implanted by surgery.
- the subject may be any suitable subject in which neuronal regeneration of the CNS is required.
- the subject may be any suitable subject with a CNS, which may require neuronal regeneration such as a mammal, for example, a cat, a dog, a horse or a human.
- the subject is a human.
- the biomaterial When the biomaterial is implanted at the site of damage in the CNS, it will promote neuronal regeneration to at least partially repair the damage. Over time, the P(TMC-CL) will be degraded and will be at least partially replaced by neural tissue.
- Figure 1 Cortical neuron culture on PLL coated films of P(T C-CL) and respective homopolymers.
- x not tested condition
- ⁇ number of cells with neurite extensions not significantly different from the control
- ⁇ number of cells without extensions not significantly different from the control.
- Figure 2 Effect of the surface on neurite elongation and cellular polarization.
- A Fluorescently labeled cortical neurons, immunostained for TAU (green); nuclei are counterstainned with Hoechst (blue);
- B Number of neurites per cell;
- C Total neurite length;
- D Average neurite length and
- Figure 3 Morphology and mechanical properties of the tested polymeric surfaces.
- A Root mean square (RMS) roughness of all polymeric surfaces;
- B Representative photographs of the polymeric surfaces before and after nanoindentation;
- C Representative nanoindentation force- displacement curves;
- D Mean hardness values of all polymeric surfaces, calculated for the maximum load and
- FIG. 4 Effect of CNS myelin on neurite outgrowth of cortical neurons cultured for 4 days on PLL-P(TMC-CL) substrates coated with CNS myelin.
- Cortical neurons are immunostained for ⁇ - ⁇ tubulin (green), myelin immunostained for MBP (red) and nuclei are counterstainned with Hoechst (blue);
- CNS neurons do not regenerate after injury due to the inhibitory environment formed by the glial scar, largely constituted by myelin debris.
- the use of biomaterials to bridge the lesion area and the creation of an environment favouring axonal regeneration is an appealing approach, currently under investigation.
- This work aims to assess the suitability of three candidate polymers - poly(e-caprolactone), poly(trimethylene carbonate- co-s-caprolactone) (P(TMC-CL)) (11 :89 mol%) and poly(trimethylene carbonate) - with the final goal of using these materials in the development of conduits to promote spinal cord regeneration.
- Poly(L-lysine) coated polymeric films were tested for neuronal cell adhesion and neurite outgrowth, with P(TMC-CL) stimulating neuronal polarization and promoting axon elongation. Furthermore, cortical neurons cultured on P(TMC-CL) in the presence of myelin were able to overcome myelin inhibition in comparison with the control condition (glass substrate). This effect was found to be mediated by the glycogen synthase kinase 3 ⁇ (GSK3p) signalling pathway with impact on the coUapsin response mediator protein 4 (CRMP4), suggesting that besides surface topography, mechanical properties were implicated in this process. The obtained results indicate P(TMC-CL) as a promising material for CNS regenerative applications as it promotes axonal growth, overcoming myelin inhibition.
- GSK3p glycogen synthase kinase 3 ⁇
- CRMP4 coUapsin response mediator protein 4
- Polymer films of 250 ⁇ in thickness were prepared by casting the polymer solution in chloroform onto glass Petri dishes. After drying the films under reduced pressure at RT, disks with a diameter of 14 mm were punched out. Prior to cell culture, disks were sterilized by two incubation steps in a 70% (v/v) ethanol solution for 15 min, followed by two rinsing steps of 15 min in autoclaved MilliQ water. After sterilization, polymer disks were placed in 24-well tissue polystyrene plates (BD Biosciences) and fixed with autoclaved silicon o-rings (EPIDOR).
- the air side surface of the polymeric disks Prior to cell seeding the air side surface of the polymeric disks was coated with 200 ⁇ of a poly(L-lysine) (PLL, Sigma) solution in a concentration ranging from 24 to 73 ⁇ g. ⁇ 1 , at 37°C for 30 min or overnight and, subsequently, rinsed with autoclaved MilliQ water.
- Coverglass (Menzel) coated with 24 ⁇ ⁇ 1 , at 37°C for 30 min was used as control.
- Wistar Han rat embryos (embryonic day 17-18) were removed by caesarean section of the euthanized pregnant rats.
- the isolated cortices were dissociated for 30 min at 37°C in Hanks Balanced Salt Solution (HBSS) supplemented with 1.0 mM pyruvate, 2 mg.ml "1 albumin, and 10% (v/v) trypsin (all from Gibco).
- Viable cells (trypan blue exclusion assay) were seeded at a density of 2.2 ⁇ 10 4 viable cells.cm "2 onto PLL-coated polymeric discs or coverglasses in 24- well cell culture plates.
- Neural cells were seeded in 300 ⁇ of Dubelcco's Modified Eagle Medium (DMEM) : Nutrient Mixture F-12 (F-12) (3:1) supplemented with 10% (v/v) inactivated fetal calf serum (FCS) (all from Gibco). Two hours later, medium and o-ring were removed and 1 ml of Neurobasal medium supplemented with 0.5 mM L-glutamine, 2% (v/v) B27 supplement, 1% (v/v) Penicillin-Streptomycin and 0.5% (v/v) Gentamicin (all from Gibco) was added and polymeric discs turned upside down. Cultures were maintained at 37 °C in a humidified atmosphere of 5 % C0 2 . Culture purity was determined by immunocytochemistry as described further down. Half of the cell culture medium was changed on the third day of culture. After 4 days in culture, samples were treated for immunocytochemistry.
- DMEM Dubelcco's Modified Eagle Medium
- F-12 Nutrient Mixture F
- Polymeric disks were coated with PLL-FITC (fluorescein isothiocyanate) (Sigma) as described in the previous section. Coverglass coated with 24 ⁇ g. ⁇ 1 of PLL, at 37°C for 30 min, was used as control. Polymeric discs coated with PLL-FITC were further mounted on microscope slides using an aqueous mounting media (Sigma) and observed with an inverted fluorescence microscope (Axiovert 200M, Zeiss). Image analysis was performed with ImageJ 1.44 software.
- PLL-FITC fluorescein isothiocyanate
- the roughness of the polymer surfaces tested for cell culture was assessed by atomic force microscopy (AFM) using a PicoPlus scanning probe microscope interface with a PicoScan controller (Agilant Technologies, USA).
- a 10x10 ⁇ 2 piezoscanner was used in tapping mode, with a scan speed of 1 line.s "1 .
- a bar shaped silicon cantilever (ACT probe, from AppNano), with a spring constant of 25-75 N.m "1 was used and roughness analysis was performed from scanned areas of 7x7 um 2 on five randomly chosen locations of each sample in air, at room temperature.
- the root-mean-square (RMS) roughness within the sampling area was determined using the WSxM scanning probe microscope software [25], according to where a represents the image height and N the total number of points.
- Force-displacement curves were obtained during loading and unloading for each indentation, and further used to determine hardness and stiffness values according to the Oliver and Pharr method [26].
- 60 indents were done on the film side tested for cell culture, covering 3 randomly chosen regions of 4 different samples per material. In each region, a set of 16 indents was made at a distance of 2 um of each other. Stiffness was calculated as the slope of the tangent line to the unloading curve at the maximum loading point and hardness values were calculated for the maximum load and taking into consideration the shape of the indenter probe.
- Myelin was isolated from brains of C57BL/6 male mice, as previously described [27]. Briefly, the isolated brains were homogenized in 0.32 M sucrose and after centrifugation at 900g, the post-nuclear supernatant was collected. The post-nuclear supernatant was carefully overlaid on an ultracentrifuge tube containing a 0.85 M sucrose solution on top of a 50% (w/v) sucrose cushion. After centrifugation for 1 hour at 37000 g at 4 °C (Sorvall Pro80 centrifuge), the interphase between sucrose solutions was transferred to a new ultracentrifuge tube. Two rounds of osmotic shocks were performed by adding ice-cold water and centrifugation at 20000 g. The final myelin pellet was stored at -80°C until further use.
- Myelin coating The polymeric disks and glass control were first coated overnight with PLL as described above and washed with 0.1M NaHC0 3 . Myelin 1.25 ⁇ g myelin.cm "2 aqueous solution was dried overnight onto the PLL coated disks as described by Cai et al. [28], and further used as substrates for cortical neuron culture.
- Neurons seeded on polymer discs in the presence of 0.05% (v/v) DMSO were used as controls. After 4 days in culture samples were treated for immunocytochemistry.
- Cortical neuron lysates were prepared by washing cells with PBS and further lysed in buffer containing 20 mM acid (MOPS), 2 raM ethylene glycol tetraacetic acid (EGTA), 5 mM emylenediaminetetraacetic acid (EDTA), 30 mM NaF, 60 mM ⁇ - glycerophosphate, 20 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1% (v/v) Triton X-100, 1% (v/v) DL-dithiothreitol (DTT), 1 mM phenylmethanesulfonyl fluoride (PMSF) and protease inhibitor cocktail (Amersham).
- MOPS 20 mM acid
- EGTA 2 raM ethylene glycol tetraacetic acid
- EDTA emylenediaminetetraacetic acid
- 30 mM NaF 60 mM
- Protein lysates (25-100 ⁇ g/lane) were run on a 12% SDS-PAGE gel and then transferred to a nitrocellulose membrane (Amersham).
- membranes were blocked with blocking buffer (5% (wt/v) non-fat dried milk in tris- buffered saline (TBS) 0.1% (v/v) Tween 20) and incubated overnight at 4°C in 5% (wt/v) bovine serum albumin (BSA) in TBS 0.1% Tween 20 with primary antibodies.
- blocking buffer 5% (wt/v) non-fat dried milk in tris- buffered saline (TBS) 0.1% (v/v) Tween 20
- BSA bovine serum albumin
- the following primary antibodies were used: rabbit anti-phospho-glycogen synthase kinase 3 beta (GSK3P) Ser9 (1:1000, Cell Signaling), rabbit anti-phospho-GSK3p Tyr216 (1:2000, Santa Cruz Biotechnology), mouse anti-GSK3a/p (1:2000, Santa Cruz Biotech.), sheep anti-phospho- collapsin response mediator protein 4 (CRMP4) Thr 509 (1:1000, Kinasource) and mouse anti- total CRMP4 (1:500, Santa Cruz Biotech.). After washing, membranes were incubated with secondary antibodies for lh at RT.
- the secondary antibodies used were anti-rabbit HRP (1:10000, Jackson Immunoresearch), anti-mouse HRP (1:10000, Thermo Scientific) and anti- goat/sheep (1:10000, Binding Site). Proteins were detected using a chemiluminescent substrate Pierce ECL western blotting substrate (Thermo Scientific) according to the manufacturer's specifications. For each experiment representative western blots are shown. Phospho-protein expression was quantified by densitometry with QuantityOne software (BioRad) and levels were normalized to the total level of the same protein.
- the amount of PLL adsorbed to the polymeric films surface was evaluated by fluorescence quantification of PLL-FITC coated samples.
- the surface area covered by PLL (in %) was only comparable to the control conditions when the polymeric films were treated with a PLL solution of at least 48 ⁇ ⁇ 1 and 72 ⁇ g. ⁇ 1 in the case of the CL containing materials and P(TMC), respectively. Consequently, cell adhesion can be directly correlated with the PLL adsorption profile to the polymeric films.
- the coating conditions used in the subsequent studies were established to be polymer surface treatment overnight with 48 ⁇ g. ⁇ l ⁇ for P(CL) and 72 ⁇ g. ⁇ 1 for P(TMC-CL) and P(TMC).
- Fig. 2A neurons behave differently on each surface. More than 80% of the cells seeded on polymeric films sho one or two neurites, while more than 80% of the cells seeded on glass (control) present between 3 to 5 neurites (Fig. 2B). Furthermore, as shown in Fig. 2A neurons seeded on the polymeric surfaces exhibit a lower degree of branching than those seeded on glass. However, 0006
- Nanoindentation is one of the most versatile techniques and particularly suited for the measurement of localized mechanical properties on the surface of materials [29].
- Representative photos of the nanoindentations and force/displacement curves are represented in Fig. 3B and C, respectively. These show that P(CL) poses a greater resistance to deformation in relation to the other two materials tested, as the force needed to achieve the same displacement is higher than for P(TMC-CL) or P(TMC).
- Fig. 3 D-E stiffness and hardness values are significantly different between the three different substrates.
- Myelin-associated inhibitors are present at a spinal cord lesion site and are known to be among the major impediments of the spontaneous axonal regeneration after SCI.
- Cortical neurons were seeded on myelin coated surfaces.
- P(TMC-CL) was chosen from the three surfaces tested as it showed the best results for neuronal adhesion and neurite extension, presenting a positive influence on axonal elongation.
- Fig. 4 when comparing surfaces coated and uncoated with myelin, the number of cells with neurites is smaller in the first case. Nevertheless, this decrease is not significant on P(TMC-CL) seeded neurons in contrast to the control where this reduction is statistically significant (p ⁇ 0.01).
- GS 3 signalling pathway mediates neuronal sensing of P(TMC-CL) surface nanomechanical properties
- GSK3 is implicated in many processes in the nervous system and is known to play a critical role in the regulation of neuron physiology. It is highly expressed in neurons and crucial for the establishment of neuronal polarity, as well as for the establishment of the branching-elongation equilibrium [30-32]. In view of this knowledge, the involvement of GSK3 as a mediator of P(TMC-CL) effect on neurite formation and axonal outgrowth was examined. GSK3P is regulated by phosphorylation and its activity can be reduced by phosphorylation at Ser-9. Contrarily, tyrosine phosphorylation at Tyr-216 increases the enzyme's activity (Fig. 5A) [33, 34]. As shown in Fig.
- cortical neurons seeded on P(TMC-CL) present lower levels of GSK3p 2 Ser-9 phosphorylation and higher level of Tyr-216 phosphorylation, in comparison to neurons cultured on glass. This indicates that neurons seeded on P(TMC-CL) display more kinase activity than those on glass. It is also perceptible from Fig. 5B that the GSK3P isoform that is differently expressed is GSK3p2, which is known to be expressed exclusively in the nervous system [35]. To further confirm the involvement of GSK3p as a mediator of the P(TMC- CL) effect on axonal outgrowth and number of neurites per cell, cortical neurons were cultured in the presence of a GSK3 pharmacologic inhibitor - BIO.
- GSK3 activity should inhibit the polymeric surface's effect on cortical neurons.
- BIO when BIO is added to the culture medium one can observe a decrease in the length of the longest neurite and in the average neurite length, as well as an increase on the number of neurites per cell. These effects occur in a dose-dependent manner, with the highest concentration of BIO tested (300 nM) leading to statistically significant differences.
- Alabed et al. [36] have established that GSK3P phosphorylation and consequent inactivation, regulates the interaction of CRMP4 and RhoA through CRMP4 de-phosphorylation.
- phospho-CRMP4 levels should be higher for neurons seeded on P(TMC-CL).
- the levels of CRMP4 phosphorylation in cortical neurons seeded on P(TMC-CL) and glass surfaces were assessed.
- phospho-CRMP4 levels were increased for neurons cultured on P(TMC-CL) as shown in Fig. 5D.
- a glial scar In the aftermath of a SCI, a glial scar is formed. Despite its key role in constraining the damaging effects caused by the lesion, the glial scar also prevents axon regeneration.
- the astroglial scar not only contains secreted and transmembrane molecular inhibitors of axon growth but also constitutes an almost impenetrable physical barrier to regeneration [4], Consequently, it was hypothethized that by creating a favourable environment at the lesion site, one will be able to enhance axonal regeneration and ultimately promote some gain of function. Therefore, the use of an implantable scaffold to bypass the glial scar area is one of the promising approaches being investigated to promote spinal cord regeneration.
- PLL is a synthetic homo-poly-(amino acid), characterized by an isopeptide bond between the ⁇ -amino and the a-carboxyl groups of L-lysine, commonly used to coat cell culture substrates [40].
- the polymer surface coating conditions were optimized - PLL concentration and time of contact - in order to achieve a comparable surface area covered by PLL and, consequently, similar cell adhesion in all tested surfaces.
- the observed PLL dependent behaviour can be explained by the different adsorption capacity of PLL on polymeric and glass surfaces. Differences that can be attributable to the surface properties of the tested materials, as these polymers present a more hydrophobic surface than glass [20], although after this process one could obtain comparable numbers of cortical neurons after 4 days of culture on the tested materials, significant morphological differences were found between neurons cultured on polymeric surfaces, particularly P(TMC-CL), and the control. Firstly, only on P(TMC-CL) the majority of neurons is able to extend neurites.
- control neurons have, on average, twice the number of neurites of neurons seeded on P(TMC-CL), when one sums the length of all neurites of each cell (total neurite length) no significant differences are found.
- cortical neurons seeded on P(TMC-CL) were found not only to be polarized but also to extend significantly longer neurites. To the best of our knowledge, no previous reports have shown this neuronal behaviour on any studied material.
- GSK3p is known to regulate axonal growth through the modification of the phosphorylation status of several microtubule-binding proteins and consequently the assembly of microtubules [34, 57].
- Alabed et al. [36] showed that the overexpression of active GSK3P attenuates MAI- dependent neurite outgrowth inhibition.
- GS 3 was studied as a possible mediator of P(TMC-CL)'s effect.
- Mammalian GSK3 is generated from two genes, GSK3a and GSK3p.
- GSK3 expression in neurons is further characterized by an alternative splicing of GSK3P originating two main variants: GSK3pi and GSK3P2.
- GSK3P2 is specifically expressed in the nervous system [34].
- GSK3p is regulated by phosphorylation and its activity is dependent on the balance between tyrosine (Tyr-216) and serine (Ser-9) phosphorylation as shown in Fig. 5A, with a reduction of activity if phosphorylated at Ser-9, and its increase if phosphorylated at Tyr-216 [33, 34].
- GSK3P activity occurs in cortical neurons when these are cultured on P(TMC-CL), resulting in an increase in neurite outgrowth and decrease on the number of neurites per cell. Increased axonal outgrowth in the presence of higher GSK3P activity has also been shown in prior reports, for cerebellar, dorsal root ganglia and hippocampal neurons [31, 36, 58].
- Rho signalling pathway is known to play an important role in neuronal growth regulation and it has been shown that inhibitors of RhoA, and/or its downstream effector Rho kinase, facilitate growth on myelin substrates [59, 60].
- Wozniak et al. [16] have studied the effects of stiffness on cell shape and shown that ROCK mediated contractility is essential for breast epithelial cells to sense the biophysical properties of the surrounding environment. Alabed et al.
- CRMP4 as a protein that functionally interacts with RhoA to mediate neurite outgrowth. Later on, this team has found that CRMP4-RhoA interaction is regulated by dephosphorylation of CRMP4 as a direct consequence of GSK3P inactivation by phosphorylation at Ser-9 [36]. This observation indicates that overexpression of GSK3P and consequent inhibition of CRMP4-RhoA complex formation may be protective in the context of myelin inhibition. Our findings are consistent with Alabed et al. [36] as for neurons seeded on P(TMC-CL), which show higher levels of GSK3 activity and longer neurites the levels of phospho-CRMP4 are higher than in glass seeded neurons. Overall these results suggest that the activation of GSK3P activity, and consequent neurite elongation, is mediated by the surface mechanical properties of P(TMC-CL).
- TMC-CL a promising material in the design of devices to promote neural regeneration, serving as a protective barrier for de novo scar tissue formation while supporting axonal growth and rendering neurons insensitive to myelin dependent neurite outgrowth inhibition without the administration of any therapeutic drug.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Mammalian central nervous system (CNS) neurons do not regenerate after injury due to the inhibitory environment formed by the glial scar, largely constituted by myelin debris. The use of biomaterials to bridge the lesion area and the creation of an environment favoring axonal regeneration is an appealing approach, currently under investigation. This work aimed at assessing the suitability of three candidate polymers - poly(?-caprolactone), poly(trimethylene carbonate-co- ?-caprolactone) (P(TMC-CL)) (11:89 mol%) and poly(trimethylene carbonate) - with the final goal of using these materials in medicine, namely in the development of conduits to promote spinal cord regeneration. Cortical neurons cultured on P(TMC-CL) in the presence of myelin were able to tame myelin inhibition in comparison with the control condition (glass substrate). This effect was found to be mediated by the glycogen synthase kinase 3p (GSK3p) signaling pathway with impact on the collapsin response mediator protein 4 (CRMP4), suggesting that nanomechanical properties were implicated in this process. The obtained results indicate P(TMC-CL) as a promising material for CNS regenerative applications as it promotes axonal growth, taming myelin inhibition.
Description
BIOM ATE RIAL COMPRISING POLY(TRIMETHYLENE CARBONATE-CO-E-CAPROLACTONE) FOR PROMOTING AXONAL GROWTH AND NEURONAL REGENERATION
Field of the Invention
The present invention relates to a biomaterial for use in medicine, in particular for promoting neuronal growth in the central nervous system, wherein the biomaterial comprises poly(trimethylene carbonate-co-8-caprolactone) (P(TMC-CL)). This biomaterial can be used in the regeneration of neurons in the central nervous system (CNS), such as the spinal cord.
Background to the Invention
When an injury is inflicted to the spinal cord, the blood-brain barrier (BBB) breaks down locally and a massive infiltration of immune cells is observed. After the initial mechanical trauma (primary damage), cell damage is triggered such that within hours the injury site and the surrounding haemorrhagic areas begin to undergo necrosis (secondary damage), a progressive process that can last for several days. Tissue necrosis is thought to result from a combination of processes, including free-radical induced injury, excitotoxic amino acids and the release of toxic cytokines by inflammatory cells. As the necrotic tissue is removed by macrophages, large fluid- filled cavities develop, which are bordered by areas of glial/connective tissue scarring. Even though this glial scar may provide several beneficial functions such as the restoration of the BBB, prevention of a devastating inflammatory response and limit action of cellular degeneration [1, 2], it also contributes to the establishment of a physical and chemical barrier to axonal regeneration [1]. Strategies aimed at preventing primary and delaying secondary damage need to be administered within minutes to hours after injury [3]. Furthermore, none of the clinical approaches currently available to control or minimize the impact of a SCI lead to neuronal regeneration [4], nor is there an efficient regenerative therapeutic strategy for SCI treatment [4]. Although injured axons show the ability to regenerate when in a peripheral nervous system environment [5], the major factor contributing to the failure of the central nervous system (CNS) regeneration is the lack of capacity of injured axons to spontaneously regenerate in the glial scar microenvironment [6].
The use of biocompatible biomaterials to bypass the glial scar is one of the promising approaches being investigated to promote spinal cord regeneration [3, 7-13]. These tissue-engineering
approaches are usually based on the use of either cell-free bridges or of cellularized biomaterial- based matrices. There are some advantages in the use of a cell-free bridging material, as on one hand cell purification and expansion methods are laborious, time consuming and expensive, and on the other hand when the transplantation of allogenic cells is required, the use of immunosuppressants cannot be circumvented [13]. Therefore the idea of a cell-free bridging material that uses and controls endogenous cell population responses, by having the ability to promote axon regeneration and control inflammatory and glial reactions is appealing.
There are numerous polymeric materials under study for application in nerve repair strategies [3, 10, 14]. These can simultaneously provide a scaffold for tissue regeneration, as well as serve as a cell-delivery vehicle and a reservoir for sustained drug delivery [15]. Within this class of materials, biodegradable polymers are particularly advantageous for the preparation of these bridges, as polymer degradation can be tuned to match the neuronal cell growth. Besides the degradation rate, the mechanical properties of the selected material are also of extreme relevance, as they must be fitted to one's needs. While the implantable structures must be flexible but relatively strong, as well as easy to handle by surgeons, their mechanical properties have an influence on cell phenotype as well [ 16- 19] .
Poly(1ximethylene carbonate-co-s-caprolactone) (P(TMC-CL)) copolymers or the parental trimethylene carbonate (TMC) homopolymer are very flexible and tough materials that can be processed into highly porous three dimensional structures with degradation rates that can be modulated by adjusting the co-monomer content [20, 21]. These materials have been shown to be biocompatible [21-23] and have been previously explored for peripheral nerve regeneration conduits [20, 23-26]. Additionally, polymer degradation occurred with minimum swelling of the material [23], which is also an essential feature to prevent nerve compression that could compromise regeneration.
Although P(TMC-CL) copolymers have been previously explored for peripheral nerve regeneration, regeneration of nerves in the CNS is hampered by the inhibitory environment formed by the glial scar, largely constituted by myelin debris. For example, it has been shown that many materials, which have shown an effect in the periphery, do not promote nerve regeneration in the CNS. Furthermore, there is no material that has been found to be able to promote axonal elongation and neuronal polarization, even in the absence of myelin (an
inhibitory substrate). Therefore, there would be no expectation that P(TMC-CL) copolymers would be able promote neuronal growth in the CNS, in particular, axonal elongation and neuronal polarization.
Summary of the Invention
In a first aspect, the present invention provides a biomaterial for use in medicine, namely for promoting neuronal regeneration in the CNS, wherein the biomaterial comprises poly(trimethylene carbonate-co-s-caprolactone) (P(TMC-CL)).
It has been surprisingly found that the copolymer poly(trimethylene carbonate-co-e- caprolactone) is able to promote neuronal regeneration, in particular, neuronal polarization and axonal elongation, in the CNS, even under inhibitory conditions. This is especially surprising as polymers of the two constituents, i.e. poly(trimethylene carbonate) and poly(8-caprolactone) do not promote this effect on their own.
The biomaterial can be used to treat conditions in which neuronal regeneration of the CNS is required. The CNS is defined as the brain and the spinal cord of a subject. The CNS does not include the sciatic nerves.
The biomaterial can be used to treat damage to the CNS. In this regard, the invention provides a biomaterial for use in treating damage to the CNS, wherein the biomaterial comprises poly(trimethylene carbonate-co-e-caprolactone) (P(TMC-CL)). This damage may occur as a result of a number of different causes. The damage may occur due to a disease, which causes damage to the CNS, or injury. For example, damage to the CNS may occur as a result of: trauma, e.g. a spinal cord injury (SCI); an infection such as poliomyelitis; neurodegeneration such as amyotrophic lateral sclerosis; a tumour; an autoimmune and/or inflammatory disease such as multiple sclerosis; or spinal stroke. Where the damage to the CNS is caused by disease, the biomaterial causes regeneration of nerves in the CNS rather than treating the underlying cause of the damage.
The biomaterial can be used to treat injury or trauma to the CNS. In particular, the biomaterial can be used to treat spinal cord injury. This typically happens as a result of damage to the spinal cord of a subject.
Poly(trimethylene carbonate-co-e-caprolactone) is a copolymer formed from the monomers trimethylene carbonate and ε-caprolactone. This copolymer can be formed in any suitable way. For example, polymerisation may be carried out using ring-opening polymerization. This may be done in an inert atmosphere such as an argon atmosphere or in solution. In some embodiments, the polymerization reaction is carried out in an inert atmosphere. A catalyst may be used such as stannous octoate or yttrium isopropoxide. In some embodiments, stannous octoate is used as a catalyst. The polymerization reaction may be carried out for a period of between 1 and 40 days depending on the temperature of polymerisation and the size of polymer required. The polymerization reaction may be carried out for a period of between 1 and 5 days. In some embodiments, the polymerization reaction is carried out for between 2 and 4 days. In particular embodiments, the polymerization reaction is carried out for 3 days. The polymerization reaction may be carried out at between about 60°C and about 200°C or between about 100°C and about 160°C. In some embodiments, the polymerisation reaction is carried out at between about 110°C and about 150°C. In further embodiments, the polymerisation reaction may be carried out at between about 120°C and about 140°C. The polymerisation reaction may be carried out at about 130°C, e.g. 130°C ± 2°C.
In certain embodiments, the polymerization reaction is carried out for between 2 and 4 days at between about 100°C and about 160°C. In some embodiments, the polymerization reaction is carried out for 3 days at between about 120°C and about 140°C such as about 130°C, e.g. 130°C ± 2°C.
The poly(trimethylene carbonate-co-E-caprolactone) contains trimethylene carbonate and ε- caprolactone as monomers. The ratio of these monomers should be such that the polymer has the required physical properties to cause neuronal regeneration in the CNS. In some embodiments, the molar ratio of trimethylene carbonate to ε-caprolactone may be between about 1 :20 and about 1:3, respectively. In other embodiments, the molar ratio of trimethylene carbonate to ε- caprolactone may be between about 1:1 and about 1:3. In further embodiments, the molar ratio of trimethylene carbonate to ε-caprolactone may be between about 1:17 and about 1:3. The molar ratio of trimethylene carbonate to ε-caprolactone may be between about 1:15 and about 1:3. In particular embodiments, the molar ratio of trimethylene carbonate to ε-caprolactone may be between about 1:20 and about 1:4. In certain embodiments, the molar ratio of trimethylene carbonate to ε-caprolactone may be between about 1:15 and about 1:5. The molar ratio of trimethylene carbonate to ε-caprolactone may be between about 1:10 and about 1 :6. Further, the
molar ratio of trimethylene carbonate to ε-caprolactone may be between about 1 :9 and about 1 :7. The molar ratio of trimethylene carbonate to ε-caprolactone may be about 1:8.
Alternatively, in some embodiments, the molar ratio of trimethylene carbonate to ε-caprolactone may be between about 5:95 and about 25:75, respectively. In other embodiments, the molar ratio of trimethylene carbonate to ε-caprolactone may be between about 5:95 and about 23:77. In further embodiments, the molar ratio of trimethylene carbonate to ε-caprolactone may be between about 5:95 and about 21:79. In particular embodiments, the molar ratio of trimethylene carbonate to ε-caprolactone may be between about 5:95 and about 19:81. In certain embodiments, the molar ratio of trimethylene carbonate to ε-caprolactone may be between about 5:95 and about 17:83. The molar ratio of trimethylene carbonate to ε-caprolactone may be between about 7:93 and about 15:85. Further, the molar ratio of trimethylene carbonate to ε- caprolactone may be between about 9:91 and about 13:87. Furthermore, the molar ratio of trimethylene carbonate to ε-caprolactone may be between about 10:90 and about 12:88. The molar ratio of trimethylene carbonate to ε-caprolactone may be about 11 :89.
The trimethylene carbonate and the ε-caprolactone should be polymerised to an appropriate degree to give a polymer with the required characteristics. The degree of polymerisation can be measured using the number average molecular weight (Mn).
The copolymer may have a number average molecular weight of at least about 0.2 x 105. The copolymer may have a number average molecular weight of less than about 2 x 105. In some embodiments, the copolymer has a number average molecular weight of less than about 1.5 x 105. The copolymer may have a number average molecular weight of less than about 1 x 105. In further embodiments, the copolymer may have a number average molecular weight of less than about 0.75 x 10s. In other embodiments, the copolymer may have a number average molecular weight of less than about 0.5 x 10s. In particular, embodiments, the copolymer has a number average molecular weight of at least about 0.2 x 105 and less than about 1 x 105. The copolymer may have a number average molecular weight of about 0.37 x 105.
The copolymer may have a stiffness of between about 200 N/m and about 400 N/m. The copolymer may have a stiffness of about 312 N/m.
The copolymer may have a hardness of between about 1 x 106 N/m2 and about 6 x 106 N/m2. In some embodiments, the copolymer has a hardness of between about 2 x 106 N/m2 and about 5 x 106 N/m2. In other embodiments, the copolymer has a hardness of between about 3 x 106 N/m2 and about 4 x 106 N/m2. The copolymer may have a hardness of about 3.32 x 106 N/m2.
The copolymer may have a roughness of between about 10 nm and about 50 nm. The copolymer may have a roughness of about 24 nm.
The poly(trimethylene carbonate-co-e-caprolactone) may be coated with a molecule that promotes cell adhesion to the polymer. This molecule may be any suitable molecule such as fibronectin, laminins (e.g. laminin-111), collagen (e.g. collagen type I), poly(ethylene imine) or synthetic oligopeptides or polypeptides (e.g. poly(L-lysine) (PLL)). In some embodiments the poly(trimethylene carbonate-co-e-caprolactone) is coated with laminin-111 or PLL. In some embodiments, the poly(trimethylene carbonate-co-e-caprolactone) is coated with PLL.
The term "about" as used herein is defined as meaning that the values referred to can vary by plus or minus 5% (i.e. ±5%).
The biomaterial and/or the P(TMC-CL) may be in any suitable form for use in promoting neuronal regeneration. For example, the biomaterial and/or the P(TMC-CL) may be in the form of a scaffold, e.g. a three dimensional scaffold. The scaffold may be porous. The biomaterial may be in the form of a nerve guide, e.g. with a hollow tubular shape (cylindrical). Such a nerve guide will serve as a conduit for axonal growth. The conduit may be constituted by an assembly of smaller diameter nerve guides. The biomaterial can also be in the form of fibres, for example, prepared from extrusion, elecfrospinning or spun from solution. These fibres can be aligned in the longitudinal orientation of the nerve fibres. The nerve guides can also be filled with the fibres. The biomaterial may be in the form of films, beads or microspheres. The biomaterial may be in the form of a patch. These can be implanted into the brain or spinal cord for promoting neuronal regeneration. The films can have topographical features, like aligned channels or poles that can be obtained by microfabrication techniques. The biomaterial and/or the P(TMC-CL) may be plasma treated to alter surface morphology and/or chemistry. The biomaterial and/or the P(TMC-CL) may comprise one or more active pharmaceutical ingredients. The pharmaceutical ingredient may be an active agent such as ibuprofen, rolipram or diclofenac.
A skilled person will appreciate that the various features described above can be combined together to form a biomaterial with certain characteristics. All the features can and are intended to be combined in any combination even if such combinations are not explicitly identified.
The present invention also provides the use of a biomaterial in the preparation of a composition for promoting neuronal regeneration in the CNS, wherein the biomaterial comprises poly(trimethylene carbonate-co-s-caprolactone) (P(TMC-CL)).
Further, the invention provides the use of a biomaterial in the preparation of a composition for treating damage to the CNS, wherein the biomaterial comprises poly(trimethylene carbonate-co- ε-caprolactone) (P(TMC-CL)).
In a further aspect, the present invention provides a method of promoting neuronal regeneration in the CNS of a subject, the method comprising administering a biomaterial comprising poly(rrimethylene carbonate-co-s-caprolactone) to a site of damage in the CNS of the subject.
The characteristics and features of the biomaterial are as described above.
The biomaterial may be administered in any suitable way. It may be implanted or injected. Generally, the biomaterial will be implanted by surgery.
The subject may be any suitable subject in which neuronal regeneration of the CNS is required. The subject may be any suitable subject with a CNS, which may require neuronal regeneration such as a mammal, for example, a cat, a dog, a horse or a human. Preferably, the subject is a human.
When the biomaterial is implanted at the site of damage in the CNS, it will promote neuronal regeneration to at least partially repair the damage. Over time, the P(TMC-CL) will be degraded and will be at least partially replaced by neural tissue.
Detailed Description of the Invention
The invention will now be described in detail, by way of example only, with reference to the following figures:
Figure 1 - Cortical neuron culture on PLL coated films of P(T C-CL) and respective homopolymers. A. Number of cortical neurons with and without neurite extensions on polymeric surfaces coated with aqueous solutions at different concentrations of PLL. Glass coated with 24 g. Γ1 of PLL for 30 minutes was used as control, (n = 3 independent studies, mean ± SD, p < 0.05) B. Percentage of PLL covered surface area as a function of the coating conditions. (n= 3, mean ± SD, p < 0.05) x = not tested condition, n.s. ~ non-signifieantly different from the control, a = total number of cells not significantly different from the control, β = number of cells with neurite extensions not significantly different from the control and χ = number of cells without extensions not significantly different from the control.
Figure 2 - Effect of the surface on neurite elongation and cellular polarization. A. Fluorescently labeled cortical neurons, immunostained for TAU (green); nuclei are counterstainned with Hoechst (blue); B. Number of neurites per cell; C. Total neurite length; D. Average neurite length and E. Length of the longest neurite. (n= 130 cells, mean ± SD, *** for p < 0.001)
Figure 3 - Morphology and mechanical properties of the tested polymeric surfaces. A. Root mean square (RMS) roughness of all polymeric surfaces; B. Representative photographs of the polymeric surfaces before and after nanoindentation; C. Representative nanoindentation force- displacement curves; D. Mean hardness values of all polymeric surfaces, calculated for the maximum load and E. Mean stiffness values for all polymeric surfaces, (n = 60 indentations, mean i SD, *** for p < 0.001)
Figure 4 - Effect of CNS myelin on neurite outgrowth of cortical neurons cultured for 4 days on PLL-P(TMC-CL) substrates coated with CNS myelin. A. Cortical neurons are immunostained for β-ΙΙΙ tubulin (green), myelin immunostained for MBP (red) and nuclei are counterstainned with Hoechst (blue); B. Effect of myelin on the ability of neurons to extend processes is presented as the % of cells with neurites in relation to the total number of cells, (n = 3 independent studies, mean ± SD; ** for p < 0.01)
Figure 5 - Analysis of GSK3 in cortical neurons plated on P(TMC-CL) and effects of GSK3P inhibition on neurite extension. A. Schematic representation of the different phosphorylation forms of GSK3p and their activity status; B. Analysis of the phosphorylated forms of GSK3p by western blot. Representative blots are shown. Expression levels of GSK3P isoforms, βΐ and β2, are presented and quantified individually or together, (n = 3 independent studies, average ± SD); C. Morphology of neurons (immunostained for Tau in green and nuclei counterstained in blue) cultured for 24 hours in the presence of DMSO (Control) or in the presence of 6-bromoindirubin- 3'-acetoxime (BIO) at 30 and 300 nM. Quantifications of the longest neurite, average neurite length and the number of neurites per cell are shown (n = 130 cells, mean ± SD, * for p < 0.05, ** for p < 0.01 and *** for p < 0.001); D. Determination of CRMP4 phosphorylation levels in cortical neurons plated for 4 days on control or P(TMC-CL). Representative western blot is shown and below the quantification (n = 3 independent studies, average ± SD).
1. SUMMARY
Mammalian central nervous system (CNS) neurons do not regenerate after injury due to the inhibitory environment formed by the glial scar, largely constituted by myelin debris. The use of biomaterials to bridge the lesion area and the creation of an environment favouring axonal regeneration is an appealing approach, currently under investigation. This work aims to assess the suitability of three candidate polymers - poly(e-caprolactone), poly(trimethylene carbonate- co-s-caprolactone) (P(TMC-CL)) (11 :89 mol%) and poly(trimethylene carbonate) - with the final goal of using these materials in the development of conduits to promote spinal cord regeneration. Poly(L-lysine) coated polymeric films were tested for neuronal cell adhesion and neurite outgrowth, with P(TMC-CL) stimulating neuronal polarization and promoting axon elongation. Furthermore, cortical neurons cultured on P(TMC-CL) in the presence of myelin were able to overcome myelin inhibition in comparison with the control condition (glass substrate). This effect was found to be mediated by the glycogen synthase kinase 3β (GSK3p) signalling pathway with impact on the coUapsin response mediator protein 4 (CRMP4), suggesting that besides surface topography, mechanical properties were implicated in this process. The obtained results indicate P(TMC-CL) as a promising material for CNS regenerative applications as it promotes axonal growth, overcoming myelin inhibition.
2. MATERIALS AND METHODS
2.1. Polymeric film preparation
Poly(trimethylene carbonate) (P(TMC), poly(s-caprolactone) (P(CL)) and poly(trimethylene carbonate-co-e-caprolactone) (P(TMC-CL)) with 11 mol % of TMC were synthesized as previously described [20]. Briefly, prior to polymerization ε-caprolactone monomer (Fluka) was dried overnight over Ca¾ and distilled under reduced pressure. Trimethylene carbonate was obtained from Boehringer Ingelheim (Germany) and used as received. Polymerizations were conducted by ring-opening polymerization in an argon atmosphere using stannous octoate as a catalyst. All polymerizations were carried out for a period of 3 days at 130°C ± 2°C. The obtained polymers were purified by dissolution in chloroform and subsequent precipitation into a ten-fold volume of ethanol. The precipitated polymers were recovered, washed with fresh ethanol and dried under reduced pressure at room temperature (RT) until constant weight. The prepared polymers were characterized with respect to chemical composition by nuclear magnetic resonance (NMR). Four hundred MHz 1H-NMR (BRUKER AVANCE III 400) spectra were recorded using solutions of polymer in CDC13 (Sigma). Number average and weight average molecular weights (Mn and Mw, respectively), polydispersity indices (PDI) and intrinsic viscosities ([η]) of the (co)polymers were determined by gel permeation chromatography (GPC, GPCmax VE-2001, Viscotek, USA). The setup was equipped with ViscoGEL I-guard-0478, ViscoGEL I-MBHMW-3078, and ViscoGEL I-MBLMW-3078 columns placed in series and a TDA 302 Triple Detector Array with refractometer, viscometer, and light-scattering detectors, allowing the determination of absolute molecular weights. All measurements were performed at 30°C, using chloroform as the eluent at a flow rate of l.O ml.min"1. The obtained results are compiled in Table 1.
Polymer films of 250 μπι in thickness were prepared by casting the polymer solution in chloroform onto glass Petri dishes. After drying the films under reduced pressure at RT, disks with a diameter of 14 mm were punched out. Prior to cell culture, disks were sterilized by two incubation steps in a 70% (v/v) ethanol solution for 15 min, followed by two rinsing steps of 15 min in autoclaved MilliQ water. After sterilization, polymer disks were placed in 24-well tissue polystyrene plates (BD Biosciences) and fixed with autoclaved silicon o-rings (EPIDOR).
2.2. Cortical neuron cell culture
Prior to cell seeding the air side surface of the polymeric disks was coated with 200 μΐ of a poly(L-lysine) (PLL, Sigma) solution in a concentration ranging from 24 to 73 μg.μ 1, at 37°C for 30 min or overnight and, subsequently, rinsed with autoclaved MilliQ water. Coverglass (Menzel) coated with 24 μ μΓ1, at 37°C for 30 min was used as control.
Wistar Han rat embryos (embryonic day 17-18) were removed by caesarean section of the euthanized pregnant rats. The isolated cortices were dissociated for 30 min at 37°C in Hanks Balanced Salt Solution (HBSS) supplemented with 1.0 mM pyruvate, 2 mg.ml"1 albumin, and 10% (v/v) trypsin (all from Gibco). Viable cells (trypan blue exclusion assay) were seeded at a density of 2.2 χ 104 viable cells.cm"2 onto PLL-coated polymeric discs or coverglasses in 24- well cell culture plates. Neural cells were seeded in 300 μΐ of Dubelcco's Modified Eagle Medium (DMEM) : Nutrient Mixture F-12 (F-12) (3:1) supplemented with 10% (v/v) inactivated fetal calf serum (FCS) (all from Gibco). Two hours later, medium and o-ring were removed and 1 ml of Neurobasal medium supplemented with 0.5 mM L-glutamine, 2% (v/v) B27 supplement, 1% (v/v) Penicillin-Streptomycin and 0.5% (v/v) Gentamicin (all from Gibco) was added and polymeric discs turned upside down. Cultures were maintained at 37 °C in a humidified atmosphere of 5 % C02. Culture purity was determined by immunocytochemistry as described further down. Half of the cell culture medium was changed on the third day of culture. After 4 days in culture, samples were treated for immunocytochemistry.
2.3. Poly(L-lysine) adsorption quantification
Polymeric disks were coated with PLL-FITC (fluorescein isothiocyanate) (Sigma) as described in the previous section. Coverglass coated with 24 μg.μ 1 of PLL, at 37°C for 30 min, was used as control. Polymeric discs coated with PLL-FITC were further mounted on microscope slides using an aqueous mounting media (Sigma) and observed with an inverted fluorescence microscope (Axiovert 200M, Zeiss). Image analysis was performed with ImageJ 1.44 software.
2.4. Atomic force microscopy
2.4.1. Roughness analysis
The roughness of the polymer surfaces tested for cell culture was assessed by atomic force microscopy (AFM) using a PicoPlus scanning probe microscope interface with a PicoScan controller (Agilant Technologies, USA). A 10x10 μπι2 piezoscanner was used in tapping mode, with a scan speed of 1 line.s"1. A bar shaped silicon cantilever (ACT probe, from AppNano), with a spring constant of 25-75 N.m"1 was used and roughness analysis was performed from scanned areas of 7x7 um2 on five randomly chosen locations of each sample in air, at room temperature. The root-mean-square (RMS) roughness within the sampling area was determined using the WSxM scanning probe microscope software [25], according to
where a represents the image height and N the total number of points.
2.4.2. Nanoindentation
These measurements were performed at CEMUP (Centro de Materials da Universidade do Porto), on a Veeco Metrology Multimode with Nanoscope IV controler (Veeco Instruments, Inc.) at RT conditions in Force-indent mode with a diamond tip, suitable for nanoindentation (DNISP Diamond-Tipped Probe from Veeco; spring constant 131 N.m"1). Deflection sensitivity of the cantilever was calibrated by indenting a sapphire surface. Nanoindentations were made for 1 second and the peak load was confined up to 30 μΝ for P(TMC-CL) and P(CL) and 6.5 uN for P(TMC). Force-displacement curves were obtained during loading and unloading for each indentation, and further used to determine hardness and stiffness values according to the Oliver and Pharr method [26]. For each polymeric substrate type, 60 indents were done on the film side tested for cell culture, covering 3 randomly chosen regions of 4 different samples per material. In each region, a set of 16 indents was made at a distance of 2 um of each other. Stiffness was calculated as the slope of the tangent line to the unloading curve at the maximum loading point and hardness values were calculated for the maximum load and taking into consideration the shape of the indenter probe.
2.5. Neurite outgrowth on myelin coated polymer films
2.5.1. Myelin isolation
Myelin was isolated from brains of C57BL/6 male mice, as previously described [27]. Briefly, the isolated brains were homogenized in 0.32 M sucrose and after centrifugation at 900g, the post-nuclear supernatant was collected. The post-nuclear supernatant was carefully overlaid on an ultracentrifuge tube containing a 0.85 M sucrose solution on top of a 50% (w/v) sucrose cushion. After centrifugation for 1 hour at 37000 g at 4 °C (Sorvall Pro80 centrifuge), the interphase between sucrose solutions was transferred to a new ultracentrifuge tube. Two rounds of osmotic shocks were performed by adding ice-cold water and centrifugation at 20000 g. The final myelin pellet was stored at -80°C until further use.
Myelin coating
The polymeric disks and glass control were first coated overnight with PLL as described above and washed with 0.1M NaHC03. Myelin 1.25 μg myelin.cm"2 aqueous solution was dried overnight onto the PLL coated disks as described by Cai et al. [28], and further used as substrates for cortical neuron culture.
2.6. Pharmacologic inhibition of glycogen synthase kinase 3
For neuronal outgrowth assays in the presence of a pharmacologic inhibitor of glycogen synthase kinase 3 (GSK3), a 30 or 300 nM solution of 6-bromoindirubin-3'-acetoxime (BIO) in dimethyl sulfoxide (DMSO) was added to cortical neuron cultures (DMSO final concentration 0.05% (v/v)) at two different time points: at seeding (t = 0) being in contact with cells for 4 days, and at the third day of culture (t = 3) being in contact with cells for 24h. Neurons seeded on polymer discs in the presence of 0.05% (v/v) DMSO were used as controls. After 4 days in culture samples were treated for immunocytochemistry.
2.7. Immunocytochemistry
Cells were fixed for immunocytochemistry staining with 2% (v/v) paraformaldehyde at RT and further permeabilized and blocked in phosphate buffered saline (PBS) containing 5% (v/v) Normal Goat Serum (NGS) (Biosource) and 0.2% (v/v) Triton X-100 (Sigma). Primary antibodies were diluted in PBS containing 1% (v/v) NGS and 0.15% (v/v) Triton X-100, and incubated overnight in a humid chamber at 4°C. Secondary antibodies were applied for lh at RT and subsequently treated for nuclear counterstaining at RT with Hoechst (Molecular Probes) at 2 μΙ.ιηΓ1. Samples were mounted directly in aqueous mounting medium and observed with an inverted fluorescence microscope.
Culture purity was >99% in cortical neurons as determined by mouse anti-glial fibrillary acid protein (GFAP) (1:500, BD Biosciences)/ mouse anti-vimentin (1:100, Thermo Scientific)/ mouse anti-oligodendrocyte marker 4 (04) (1:100, Chemicon)/ rabbit anti-Tau (TAU protein) (1:100, Sigma)/ 2 ug-ml"1 Hoechst fluorescent staining. Cells were counted from 18 radial fields and values were extrapolated to the total surface area of the sample (n=3). For axonal outgrowth assessment the length of the longest neurite and total neurite outgrowth per cell were determined using Axio Vision image analysis software. Neuronal processes were manually traced and quantified on 130 cells per condition. Three independent experiments were performed.
For neuronal outgrowth analysis on myelin inhibition studies, neurons were stained with anti-βΙΙΙ tubulin (1:500, Abeam) and myelin with anti-myelin basic protein (MBP) SMI-94 (1:500, Abeam). The secondary antibodies used were anti-rabbit Alexa 488 (1:500, Invitrogen), anti- mouse 594 (1:1000, Invitrogen).
2.8. Western Blot
Cortical neuron lysates were prepared by washing cells with PBS and further lysed in buffer containing 20 mM
acid (MOPS), 2 raM ethylene glycol tetraacetic acid (EGTA), 5 mM emylenediaminetetraacetic acid (EDTA), 30 mM NaF, 60 mM β- glycerophosphate, 20 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1% (v/v) Triton X-100, 1% (v/v) DL-dithiothreitol (DTT), 1 mM phenylmethanesulfonyl fluoride (PMSF) and protease inhibitor cocktail (Amersham). Protein lysates (25-100 μg/lane) were run on a 12% SDS-PAGE gel and then transferred to a nitrocellulose membrane (Amersham). For Western analysis, membranes were blocked with blocking buffer (5% (wt/v) non-fat dried milk in tris- buffered saline (TBS) 0.1% (v/v) Tween 20) and incubated overnight at 4°C in 5% (wt/v) bovine serum albumin (BSA) in TBS 0.1% Tween 20 with primary antibodies. The following primary antibodies were used: rabbit anti-phospho-glycogen synthase kinase 3 beta (GSK3P) Ser9 (1:1000, Cell Signaling), rabbit anti-phospho-GSK3p Tyr216 (1:2000, Santa Cruz Biotechnology), mouse anti-GSK3a/p (1:2000, Santa Cruz Biotech.), sheep anti-phospho- collapsin response mediator protein 4 (CRMP4) Thr 509 (1:1000, Kinasource) and mouse anti- total CRMP4 (1:500, Santa Cruz Biotech.). After washing, membranes were incubated with secondary antibodies for lh at RT. The secondary antibodies used were anti-rabbit HRP (1:10000, Jackson Immunoresearch), anti-mouse HRP (1:10000, Thermo Scientific) and anti- goat/sheep (1:10000, Binding Site). Proteins were detected using a chemiluminescent substrate Pierce ECL western blotting substrate (Thermo Scientific) according to the manufacturer's specifications. For each experiment representative western blots are shown. Phospho-protein expression was quantified by densitometry with QuantityOne software (BioRad) and levels were normalized to the total level of the same protein.
2.9. Statistical Analysis
For statistical analysis, one-way ANOVA followed by Tukey's post-hoc test were used. When Gaussian distribution was not confirmed non-parametric test Man- Whitney was applied, using
the Graphpad Prism program. Data is expressed as the mean ± standard deviation (SD) and p values of < 0.05 were considered significant.
3. RESULTS
3.1. Cortical neurons adhere and extend neurites in a PLL dependent manner
As a first step in assessing P(CL), P(TMC-CL) and P(TMC) compatibility with the CNS and their potential application in devices for neuroregeneration, polymeric discs were tested as substrates for cortical neuron growth in vitro. Cortical neurons were seeded on PLL coated polymeric films and were found to adhere to the tested substrates in a PLL concentration dependent manner (Fig. 1A). Cell number and neurite outgrowth on the coated polymeric films were evaluated using coverglasses coated with a PLL concentration of 24 μ μ 1 for 30 min as control. Cortical neurons adhered in comparable numbers to the control when these were coated overnight with 24 μg.μ 1 and 48 μg.μ 1 of PLL in the case of P(CL) films, and 72 μg.μ 1 of PLL in the case of TMC containing films (see Fig. 1A). However, only on P(TMC-CL) the majority of adhered cells was able to extend neurites as in the control.
To explain this PLL-dependent behaviour, the amount of PLL adsorbed to the polymeric films surface was evaluated by fluorescence quantification of PLL-FITC coated samples. As one can observe in Fig. IB, the surface area covered by PLL (in %) was only comparable to the control conditions when the polymeric films were treated with a PLL solution of at least 48 μ μΓ1 and 72 μg.μΓ1 in the case of the CL containing materials and P(TMC), respectively. Consequently, cell adhesion can be directly correlated with the PLL adsorption profile to the polymeric films. Taking into consideration the obtained results, both in terms of cell adhesion and neurite extension, the coating conditions used in the subsequent studies were established to be polymer surface treatment overnight with 48 μg.μlΛ for P(CL) and 72 μg.μ 1 for P(TMC-CL) and P(TMC).
3.2. P(TMC-CL) stimulates axonal elongation
In order to evaluate neurite outgrowth on the different PLL-coated polymeric surfaces, the number of neurites per cell, as well as the neurite length were determined. As seen in Fig. 2A, neurons behave differently on each surface. More than 80% of the cells seeded on polymeric films sho one or two neurites, while more than 80% of the cells seeded on glass (control) present between 3 to 5 neurites (Fig. 2B). Furthermore, as shown in Fig. 2A neurons seeded on the polymeric surfaces exhibit a lower degree of branching than those seeded on glass. However,
0006
16
on P(CL) and P(TMC) the adhered cells show smaller neurites than on P(TMC-CL) and the control (Fig. 2C-E). Despite the fact that for P(TMC-CL) the total neurite length was similar to the one observed on glass, given the lower number of neurites per cell in this condition, the average neurite length was higher (Fig. 2D). More remarkably, the length of the longest neurite was increased relatively to the control (Fig. 2E).
3.3. P(TMC-CL)'s mechanical properties stimulate axonal outgrowth
As shown in Fig. 3 A, AFM analysis indicated that the RMS roughness was similar for P(CL) and P(TMC-CL), with mean values of 21.8 ± 11.5 nm and 24.4 ± 12.1 nm respectively, while significantly lower for P(TMC) with a mean value of 1.6 nm ± 1.0.
Nanoindentation is one of the most versatile techniques and particularly suited for the measurement of localized mechanical properties on the surface of materials [29]. Representative photos of the nanoindentations and force/displacement curves are represented in Fig. 3B and C, respectively. These show that P(CL) poses a greater resistance to deformation in relation to the other two materials tested, as the force needed to achieve the same displacement is higher than for P(TMC-CL) or P(TMC). As shown in Fig. 3 D-E stiffness and hardness values are significantly different between the three different substrates. A stiffness value of 312 ± 56.4 N.m" 1 and a hardness of 3.32 xlO6 ± 0.373 x 106 N.m-2 was found for P(TMC-CL), while P(CL) shows the highest values with a stiffness of 435 ± 40.4 N.m"1 and a hardness value of 6.60 xlO6 ± 2.11 x 106 N.m-2. As seen in the photos before and after nanoindentation, P(TMC) samples recover almost completely from the indentations and, consequently, show stiffness and hardness values close to zero.
3.4. P(TMC-CL) promotes overcome of myelin inhibition
Myelin-associated inhibitors (MAIs) are present at a spinal cord lesion site and are known to be among the major impediments of the spontaneous axonal regeneration after SCI. Cortical neurons were seeded on myelin coated surfaces. P(TMC-CL) was chosen from the three surfaces tested as it showed the best results for neuronal adhesion and neurite extension, presenting a positive influence on axonal elongation. As seen in Fig. 4, when comparing surfaces coated and uncoated with myelin, the number of cells with neurites is smaller in the first case. Nevertheless, this decrease is not significant on P(TMC-CL) seeded neurons in contrast to the control where this reduction is statistically significant (p < 0.01).
3.5. GS 3 signalling pathway mediates neuronal sensing of P(TMC-CL) surface nanomechanical properties
GSK3 is implicated in many processes in the nervous system and is known to play a critical role in the regulation of neuron physiology. It is highly expressed in neurons and crucial for the establishment of neuronal polarity, as well as for the establishment of the branching-elongation equilibrium [30-32]. In view of this knowledge, the involvement of GSK3 as a mediator of P(TMC-CL) effect on neurite formation and axonal outgrowth was examined. GSK3P is regulated by phosphorylation and its activity can be reduced by phosphorylation at Ser-9. Contrarily, tyrosine phosphorylation at Tyr-216 increases the enzyme's activity (Fig. 5A) [33, 34]. As shown in Fig. 5B cortical neurons seeded on P(TMC-CL) present lower levels of GSK3p2 Ser-9 phosphorylation and higher level of Tyr-216 phosphorylation, in comparison to neurons cultured on glass. This indicates that neurons seeded on P(TMC-CL) display more kinase activity than those on glass. It is also perceptible from Fig. 5B that the GSK3P isoform that is differently expressed is GSK3p2, which is known to be expressed exclusively in the nervous system [35]. To further confirm the involvement of GSK3p as a mediator of the P(TMC- CL) effect on axonal outgrowth and number of neurites per cell, cortical neurons were cultured in the presence of a GSK3 pharmacologic inhibitor - BIO. It is expected that inhibiting GSK3 activity should inhibit the polymeric surface's effect on cortical neurons. In fact, as shown in Fig. 5C, when BIO is added to the culture medium one can observe a decrease in the length of the longest neurite and in the average neurite length, as well as an increase on the number of neurites per cell. These effects occur in a dose-dependent manner, with the highest concentration of BIO tested (300 nM) leading to statistically significant differences. Alabed et al. [36] have established that GSK3P phosphorylation and consequent inactivation, regulates the interaction of CRMP4 and RhoA through CRMP4 de-phosphorylation. If this mechanism is active in our setup, phospho-CRMP4 levels should be higher for neurons seeded on P(TMC-CL). To test this hypothesis, the levels of CRMP4 phosphorylation in cortical neurons seeded on P(TMC-CL) and glass surfaces were assessed. As expected, phospho-CRMP4 levels were increased for neurons cultured on P(TMC-CL) as shown in Fig. 5D.
4. DISCUSSION
In the aftermath of a SCI, a glial scar is formed. Despite its key role in constraining the damaging effects caused by the lesion, the glial scar also prevents axon regeneration. The
astroglial scar not only contains secreted and transmembrane molecular inhibitors of axon growth but also constitutes an almost impenetrable physical barrier to regeneration [4], Consequently, it was hypothethized that by creating a favourable environment at the lesion site, one will be able to enhance axonal regeneration and ultimately promote some gain of function. Therefore, the use of an implantable scaffold to bypass the glial scar area is one of the promising approaches being investigated to promote spinal cord regeneration. A prerequisite in the design of such biomaterial is its biocompatibility, which in this context means that it must support neuronal survival and axonal growth. The aim of this study was, therefore, to investigate the suitability of P(CL), P(TMC-CL) and P(TMC) as substrates for spinal cord regeneration purposes.
One of the most commonly used strategies to assess neuronal behaviour in vitro when testing biomaterials for nerve regeneration applications is to evaluate axonal growth [28, 36-39]. In the present work rat cortical neurons were firstly seeded on the PLL-coated polymeric substrates to assess adhesion and neurite outgrowth ability. PLL is a synthetic homo-poly-(amino acid), characterized by an isopeptide bond between the ε-amino and the a-carboxyl groups of L-lysine, commonly used to coat cell culture substrates [40]. Initially, the polymer surface coating conditions were optimized - PLL concentration and time of contact - in order to achieve a comparable surface area covered by PLL and, consequently, similar cell adhesion in all tested surfaces. The observed PLL dependent behaviour can be explained by the different adsorption capacity of PLL on polymeric and glass surfaces. Differences that can be attributable to the surface properties of the tested materials, as these polymers present a more hydrophobic surface than glass [20], although after this process one could obtain comparable numbers of cortical neurons after 4 days of culture on the tested materials, significant morphological differences were found between neurons cultured on polymeric surfaces, particularly P(TMC-CL), and the control. Firstly, only on P(TMC-CL) the majority of neurons is able to extend neurites. Furthermore, our results show that among all the tested surfaces, including glass, seeding cortical neurons on P(TMC-CL) stimulates neuronal polarization and promotes axon elongation, as neurons on P(TMC-CL) show significantly enhanced neurite outgrowth and significantly lower numbers of neurites per cell. This switch to polarized and elongated morphology is noteworthy as successful regeneration requires that neurons survive and initiate rapid and directed neurite outgrowth [41]. A decreased number of neurites per cell were also found on P(CL) and P(TMC) but on these materials axonal outgrowth was significantly impaired. Moreover, while control
neurons have, on average, twice the number of neurites of neurons seeded on P(TMC-CL), when one sums the length of all neurites of each cell (total neurite length) no significant differences are found. Altogether, cortical neurons seeded on P(TMC-CL) were found not only to be polarized but also to extend significantly longer neurites. To the best of our knowledge, no previous reports have shown this neuronal behaviour on any studied material.
The potential of materials to trigger specific cellular responses is getting to be a well established phenomenon mediated by a number of factors that range from the properties of the surface that contacts with the cell, to the mechanical properties of the material [16, 17, 42-44]. We have previously characterized the family of these copolymers and when varying the monomer ratio mainly the thermal and, consequently, the mechanical properties of these materials are drastically affected [21]. P(TMC) and P(TMC-CL) copolymers with high CL content are flexible and though materials that range from amorphous to semi-crystaline elastomers when the CL content increases. Therefore, we hypothesise that surface topography and the nanomechanical properties of the tested materials play a key role in influencing cell behaviour. The local characterization of roughness, hardness and elastic properties of a wide range of materials has been reported including for thin films and biomolecules [45-48] but so far the characterization of TMC-CL copolymers has not been performed. The roughness of the three tested polymeric surfaces was first investigated. Values of 22 nm and 24 nm were found for P(CL) and P(TMC- CL) respectively, while for the P(TMC) the roughness values were found to be significantly lower. In 2002, Fan et al. [49, 50] showed that neuronal cells adherence and survival is optimum on surfaces with a RMS roughness ranging from 10 to 50 nm. Taking this data in consideration, both P(CL) and P(TMC-CL) show not only similar but also optimum roughness values for neural adhesion and survival, while P(TMC) is outside this optimum roughness range. Therefore, the different neuronal behaviour on these surfaces cannot be explained simply by topography. Aiming to measure localized mechanical properties on the surface of the polymeric films, nanoindentations were performed and force-displacement curves obtained for each indentation. Mean hardness and stiffness values were calculated and significant differences were found between all polymeric surfaces, with P(TMC-CL) being significantly less resistant to deformation than P(CL) and significantly more resistant to deformation than P(TMC). Although roughness values were similar between P(CL) and P(TMC-CL) and within the optimum range, P(CL) was two times harder than P(TMC-CL), which could explain the different cellular
behaviour on these surfaces, indicating that changes in stiffness and hardness values may have caused changes in cell morphology, specifically in axonal elongation.
Having observed the ability of P(TMC-CL) surfaces in promoting neuronal polarization and axonal elongation under normal cell culture conditions, the capacity of P(TMC-CL) to positively affect cortical neurons in a typical CNS inhibitory environment was tested, envisaging its application in the design of an axonal regeneration promoting strategy. While axons in the context of a mature mammalian CNS do not regenerate if damaged, the immature mammalian CNS is able to regenerate after injury [51, 52]. Probably the most notable difference between the mature and the immature nervous system is the presence of myelin [28]. Indeed, the limited regenerative capacity of the mammalian CNS is known to be partially due to myelin inhibition. So far, no biomaterial has shown the ability to overcome myelin inhibition unless blockers of myelin protein receptors were used [53]. Recently, Mohammad and co-workers have shown that a nano-textured self-assembled aligned collagen hydrogel was able to promote directional neurite guidance and overcome inhibition by a recombinant myelin-associated glycoprotein of dorsal root ganglia cultures [54]. To assess P(TMC-CL)'s neuronal effect under adverse, and more biologically relevant conditions, cortical neurons were seeded on P(TMC-CL) films in the presence of myelin. As expected, in the glass control surface we observed a statistically significant reduction of the number of cells extending neurites when cultured in the presence of myelin. In contrast, when P(TMC-CL) was used as a substrate, this reduction was not statistically significant (Fig. 4 B), suggesting that P(TMC-CL) is, to some extent, contributing to the promotion of the overcome of myelin inhibition. This is of extreme relevance as it has been already demonstrated that some degree of functional recovery can be obtained simply by counteracting the activity of myelin inhibition [55, 56]. The existence of a biomaterial that has the capacity to overcome this inhibition per se, without the need for the administration of antibodies or chemical inhibitors, can prove to be of great importance for therapeutic purposes.
The potential of materials to trigger specific cellular responses, such as interference and/or activation of defined pathways is extremely promising for tissue engineering. Stiffness and hardness sensing probably involves transduction into biological signals [17]. GSK3p is known to regulate axonal growth through the modification of the phosphorylation status of several microtubule-binding proteins and consequently the assembly of microtubules [34, 57]. Moreover, Alabed et al. [36] showed that the overexpression of active GSK3P attenuates MAI-
dependent neurite outgrowth inhibition. For these reasons, GS 3 was studied as a possible mediator of P(TMC-CL)'s effect. Mammalian GSK3 is generated from two genes, GSK3a and GSK3p. GSK3 expression in neurons is further characterized by an alternative splicing of GSK3P originating two main variants: GSK3pi and GSK3P2. GSK3P2 is specifically expressed in the nervous system [34]. GSK3p is regulated by phosphorylation and its activity is dependent on the balance between tyrosine (Tyr-216) and serine (Ser-9) phosphorylation as shown in Fig. 5A, with a reduction of activity if phosphorylated at Ser-9, and its increase if phosphorylated at Tyr-216 [33, 34]. Our results show that GSK3P is differently regulated in neurons seeded on glass and P(TMC-CL), with the later showing lower levels of Ser9 phosphorylation, a site of GSK3P inactivation, and higher levels of Tyr216 phosphorylation, which facilitates the activity of GSK3p by promoting substrate accessibility [34]. Neurite elongation and neuronal polarization on P(TMC-CL) may be promoted by an increase GSK3p activity in vitro. The relationship between axonal elongation and GSK3P activity was further confirmed through pharmacological inhibition of GS 3 in vitro. As expected, inhibition of GSK3P blocked P(TMC-CL) effect, as there was a decrease in neurite length and an increase on the numbers of neurites per cell. Cells seeded on P(TMC-CL) and treated with BIO acquired a morphology that resembles more closely the neurons seeded on glass Fig. 2A.
Activation of GSK3P activity occurs in cortical neurons when these are cultured on P(TMC-CL), resulting in an increase in neurite outgrowth and decrease on the number of neurites per cell. Increased axonal outgrowth in the presence of higher GSK3P activity has also been shown in prior reports, for cerebellar, dorsal root ganglia and hippocampal neurons [31, 36, 58].
The Rho signalling pathway is known to play an important role in neuronal growth regulation and it has been shown that inhibitors of RhoA, and/or its downstream effector Rho kinase, facilitate growth on myelin substrates [59, 60]. Wozniak et al. [16] have studied the effects of stiffness on cell shape and shown that ROCK mediated contractility is essential for breast epithelial cells to sense the biophysical properties of the surrounding environment. Alabed et al.
[61] have identified CRMP4 as a protein that functionally interacts with RhoA to mediate neurite outgrowth. Later on, this team has found that CRMP4-RhoA interaction is regulated by dephosphorylation of CRMP4 as a direct consequence of GSK3P inactivation by phosphorylation at Ser-9 [36]. This observation indicates that overexpression of GSK3P and consequent inhibition of CRMP4-RhoA complex formation may be protective in the context of
myelin inhibition. Our findings are consistent with Alabed et al. [36] as for neurons seeded on P(TMC-CL), which show higher levels of GSK3 activity and longer neurites the levels of phospho-CRMP4 are higher than in glass seeded neurons. Overall these results suggest that the activation of GSK3P activity, and consequent neurite elongation, is mediated by the surface mechanical properties of P(TMC-CL).
5. CONCLUSIONS
This work shows that P(TMC-CL) with a high CL content can promote axonal regeneration, prompting neurons into a regeneration mode, even under inhibitory conditions. This effect is mediated by the GSK3 signalling pathway, which is triggered by P(TMC-CL)'s surface mechanical properties.
These findings establish P(TMC-CL) as a promising material in the design of devices to promote neural regeneration, serving as a protective barrier for de novo scar tissue formation while supporting axonal growth and rendering neurons insensitive to myelin dependent neurite outgrowth inhibition without the administration of any therapeutic drug.
REFERENCES
1. Silver J, Miller JH. Nature Reviews Neuroscience 2004;5(2): 146- 156.
2. Schwab JM, Brechtel K, Mueller CA, Failli V, Kaps HP, Tuli SK, et al. Progress in Neurobiology 2006;78(2):91-116.
3. Madigan NN, McMahon S, O'Brien T, Yaszemski MJ, Windebank A J. Respiratory Physiology and Neurobiology 2009;169(2):183-199.
4. Thuret S, Moon LDF, Gage FH. Nature Reviews Neuroscience 2006;7(8):628-643.
5. Richardson PM, McGuinness UM, Aguayo AJ. Nature 1980;284(5753):264-265.
6. Prang P, Muller R, Eljaouhari A, Heckmann K, Kunz W, Weber T, et al. Biomaterials 2006;27(19):3560-3569.
7. Willerth S, Sakiyama-Elbert S. Advanced Drug Delivery Reviews 2007;59(4-5):325-338.
8. Friedman J A, Windebank AJ, Moore MJ, Spinner RJ, Currier BL, Yaszemski MJ, et al. Neurosurgery 2002;51(3):742-752.
9. Straley KS, Foo CWP, Heilshorn SC. Journal of Neurotrauma 2010;27(1):1-19.
10. Novikova L, Novikov L, Kellerth J. Current Opinion in Neurology 2003;16(6):711-715.
11. Wong DY, Leveque JC, Brumblay H, Krebsbach PH, Hollister SJ, LaMarca F. Journal of Neurotrauma 2008;25(8):1027-1037.
12. Zhang N, Yan H, Wen X. Brain Research Reviews 2005;49(1 ):48-64.
13. Geller HM, Fawcett JW. Experimental Neurology 2002;174(2):125-136.
14. Pego AP, Kubinova S, Cizkiva D, Vanicky I, Mar FM, Sousa MM, et al. Journal of Cellular and Molecular Medicine 2012.
15. Chen BK, Knight AM, De Ruiter GCW, Spinner RJ, Yaszemski MJ, Currier BL, et al. Journal of Neurotrauma 2009;26(10): 1759-1771.
16. Wozniak MA, Desai R, Solski PA, Der CJ, Keely PJ. Journal of Cell Biology 2003;163(3):583-595.
17. Chen CS. Journal of Cell Science 2008;121(20):3285-3292.
18. Schuh E, Hofmann S, Stok KS, Notbohm H, Muller R, Rotter N. Journal of Tissue Engineering and Regenerative Medicine 2011.
19. Fioretta ES, Fledderus JO, Baaijens FPT, Bouten CVC. Journal of Biomechanics 2012;45(5):736-744.
20. Pego AP, Poot AA, Grijpma DW, Feijen J. Journal of Biomaterials Science, Polymer Edition 2001;12(l):35-53.
21. Pego AP, Poot A, Grijpma D, Feijen J. Macromolecular Bioscience 2002;2(9):411-419.
22. Pego AP, Van Luyn MJA, Brouwer LA, Van Wachem PB, Poot AA, Grijpma DW, et al. Journal of Biomedical Materials Research - Part A 2003 ;67(3): 1044- 1054.
23. Vleggeert-Lankamp CLAM, De Ruiter GCW, Wolfs JFC, Pego AP, Feirabend HKP, Lakke EAJF, et al. European Journal of Neuroscience 2005;21(5):1249-1256.
24. Vleggeert-Lankamp CLAM, Wolfs J, Pego AP, Van Den Berg R, Feirabend H, Lakke E. Journal of Neurosurgery 2008;109(2):294-305.
25. Horcas I, Fernandez R, Gomez-Rodriguez JM, Colchero J, Gomez-Herrero J, Baro AM. Review of Scientific Instruments 2007;78(1).
26. Hobbs JK, Winkel AK, McMaster TJ, Humphris ADL, Baker AA, Blakely S, et al. Macromolecular Symposia 2001;167:15-43.
27. Norton WT PS. J Neurochem 1973;21(4):749-757.
28. Cai D, Yingjing S, De Bellard ME, Tang S, Filbin MT. Neuron 1999;22(1):89-101.
29. urland NE, Drira Z, Yadavalli VK. Micron 2012;43(2-3): 116-128.
30. Peineau S. BC, Taghibiglou C, Doherty A., Bortolotto Z. A., Wang Y. T. and Collingridge G.L. Br J Pharmacol 2008;153(Suppl. 1):S428-S437.
31. Juan Jose Garrido DS, Varea O, Wandosell F. FEBS lett 2007;581:1579-1586.
32. Li R. Current Biology 2005; 15(6):R198-R200.
33. Grimes CA, Jope RS. Progress in Neurobiology 2001;65(4):391-426.
34. Hur EM, Zhou FQ. Nature Reviews Neuroscience 2010;11(8):539-551.
35. Castano Z, Gordon- Weeks P, Kypta R. Journal Neurochemistry 2010;113(1):117-130.
36. Alabed YZ, Pool M, Tone SO, Sutherland C, Fournier AE. Journal of Neuroscience 2010;30(16):5635-5643.
37. Fournier AE, GrandPre T, Strittmatter SM. Nature 2001;409(6818):341-346.
38. Fu Q, Hue J, Li S. Journal of Neuroscience 2007;27(15):4154- 164.
39. Oscar Siera RG, Vanessa Gil, Franc Llorens, Alejandra Rangel, Eduardo Soriano, and Jose Antonio del Rio. Journal of Neurochemistry 2010;113:1644-1658.
40. Muller H-J, Roder T. Microarrays: Elsevier Academic Press, 2006.
41. Cafferty WBJ, Gardiner NJ, Gavazzi I, Powell J, McMahon SB, Heath JK, et al. Journal of Neuroscience 2001;21(18):7161-7170.
42. Leach JB, Brown XQ, Jacot JG, Dimilla PA, Wong JY. Journal of Neural Engineering 2007;4(2):26-34.
43. Pelham Jr RJ, Wang YL. Proceedings of the National Academy of Sciences of the United States of America 1997;94(25): 13661-13665.
44. Brunetti V, Maiorano G, Rizzello L, Sorce B, Sabella S, Cingolani R, et al. Proceedings of the National Academy of Sciences of the United States of America 2010;107(14):6264-6269.
45. Radmacher JDaM. Langmuir 1998;14:3320-3325.
46. Kinney JH, Marshall GM, Marshall S J. Archives of oral Biology 1999;44: 813 -822.
47. Kol N, Shi Y, Tsvitov M, Barlam D, Shneck RZ, Kay MS, et al. Biophysical Journal 2007;92(5):1777-1783.
48. G. W. Marshall MB, R. R. Gallagher, S. A. Gansky, S. J. Marshall. J Biomed Mat Res 2001;54:87-95.
49. Fan YW, Cui FZ, Chen LN, Zhai Y, Xu QY, Lee IS. Applied Surface Science 2002;187(3a€'4):313-318.
50. Fan YW, Cui FZ, Hou SP, Xu QY, Chen LN, Lee IS. Journal of Neuroscience Methods 2002;120(l):17-23.
51. Bates CA, Stelzner DJ. Experimental Neurology 1993;123(1):106-117.
52. Hasan S, Keirstead H, Muir G, Steeves J. Journal of Neuroscience 1993;13(2):492-507.
53. Yue-Teng Wei YH, Chand-Lei Xu, Ying Wang, Bing-Fang Liu, Xiu-Mei Wang, Xiao- Dan Sun, Fu-Zhai Cui, Qun-Yuan Xu. Journal of Biomedical Materials Research 2010;95B(1):110-117.
54. Abu-Rub MT, Billiar KL, Van Es MH, Knight A, Rodriguez BJ, Zeugolis DI, et al. Soft Matter;7(6):2770-2781.
55. Bregman BS, Kunkel-Bagden E, Schnell L, Dai HN, Gao D, Schwab ME. Nature 1995;378(6556):498-501.
56. Schnell L, Schwab ME. Nature 1990;343(6255):269-272.
57. Dill J, Wang H, Zhou F, Li S. Journal of Neuroscience 2008;28(36):8914-8928.
58. Kim WY, Zhou FQ, Zhou J, Yokota Y, Wang YM, Yoshimura T, et al. Neuron 2006;52(6):981-996.
59. Dergham P, EUezam B, Essagian C, Avedissian H, Lubell WD, McKerracher L. Journal of Neuroscience 2002;22(15):6570-6577.
60. Lehmann MAF, Selles-Navarro I, Dergham P, Sebok, A Leclerc N, Tigyi G, McKerracher L. The Journal of Neuroscience 1999;19(17):7537-7547.
61. Alabed Y, Pool M, Tone S, Fournier A. J. Neuroscience 2007;27(7):1702-1711.
Claims
1. A biomaterial for use in medicine, wherein the biomaterial comprises poly(trimethylene carbonate-co-e-caprolactone) (P(TMC-CL)).
2. A biomaterial for use in promoting neuronal regeneration in the central nervous system, wherein the biomaterial comprises poly(trimethylene carbonate-co-s-caprolactone) (P(TMC-CL)).
3. The biomaterial for use according to claim 2, wherein the biomaterial is for use in treating damage to the central nervous system.
4. The biomaterial for use according to claim 3, wherein the damage is a traumatic injury.
5. The biomaterial for use according to claim 4, wherein the damage is a spinal cord injury (SCI).
6. The biomaterial for use according to claim 3, wherein the damage is as a result of a disease which causes damage to the CNS such as the spinal cord.
7. The biomaterial for use according to claim 3 or claim 6, wherein the damage is caused by: an infection such as poliomyelitis; neurodegeneration such as amyotrophic lateral sclerosis; a tumour; an autoimmune and/or inflammatory disease such as multiple sclerosis; or spinal stroke.
8. The biomaterial for use according to any preceding claim, wherein the molar ratio of trimethylene carbonate to ε-caprolactone in the P(TMC-CL) is between about 1 :20 and about 1:3.
9. The biomaterial for use according to any preceding claim, wherein the molar ratio of trimethylene carbonate to ε-caprolactone in the P(TMC-CL) is between about 1:10 and about 1:6.
10. The biomaterial for use according to any preceding claim, wherein the molar ratio of trimethylene carbonate to ε-caprolactone in the P(TMC-CL) is about 11:89.
11. The biomaterial for use according to any preceding claim, wherein the P(TMC-CL) is coated with a molecule that promotes cell adhesion.
12. The biomaterial for use according to claim 10, wherein the molecule that promotes cell adhesion is poly(L-lysine) (PLL).
13. The biomaterial for use according to any preceding claim, wherein the P(TMC-CL) has a number average molecular weight of at least about 0.2 x 105.
14. The biomaterial for use according to any preceding claim, wherein the P(TMC-CL) has a number average molecular weight of less than about 2 x 10s.
15. The biomaterial for use according to any preceding claim, wherein the P(TMC-CL) has a stiffness of between about 200 N/m and about 400 N/m.
16. The biomaterial for use according to any preceding claim, wherein the P(TMC-CL) has a hardness of between about 1 x 106 N/m2 and about 6 x 106 N/m2.
17. The biomaterial for use according to any preceding claim, wherein the P(TMC-CL) has a roughness of between about 10 nm and about 50 nm.
18. The biomaterial for use according to any preceding claim, wherein the biomaterial is in the form of a scaffold, a nerve guide, a fibre, a film, a bead, a microsphere, or a patch.
19. The biomaterial for use according to any preceding claim, wherein the biomaterial is in the form of a scaffold or a nerve guide.
20. The biomaterial for use according to any one of claims 1 to 17, wherein the biomaterial is in the form of a patch.
27
21. The biomaterial for use according to any preceding claim, wherein the biomaterial comprises one or more active pharmaceutical ingredients.
22. A method of promoting neuronal regeneration in the central nervous system of a subject, the method comprising administering a biomaterial comprising poly(trimethyIene carbonate-co-e-caprolactone) to a site of damage in the central nervous system of the subject.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14710658.7A EP2948155A1 (en) | 2013-01-28 | 2014-01-28 | Biomaterial comprising poly(trimethylene carbonate-co-e-caprolactone) for promoting axonall growth and neuronal regeneration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1301461.8A GB201301461D0 (en) | 2013-01-28 | 2013-01-28 | Biomaterial |
GB1301461.8 | 2013-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014116132A1 true WO2014116132A1 (en) | 2014-07-31 |
Family
ID=47890876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/PT2014/000006 WO2014116132A1 (en) | 2013-01-28 | 2014-01-28 | Biomaterial comprising poly(trimethylene carbonate-co-e-caprolactone) for promoting axonall growth and neuronal regeneration |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2948155A1 (en) |
GB (1) | GB201301461D0 (en) |
WO (1) | WO2014116132A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3006055A1 (en) * | 2014-10-10 | 2016-04-13 | Albert-Ludwigs-Universität Freiburg | Improved biomaterials for neuronal implants and use of said biomaterials in the diagnosis and therapy of neuronal diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004041318A1 (en) * | 2002-11-05 | 2004-05-21 | Universiteit Twente | Method for providing shaped biodegradable and elastomeric structures of (co) polymers of 1,3-trimethylene carbonate (tmc), shaped biodegradable and elastomeric structures, and the use of these structures |
-
2013
- 2013-01-28 GB GBGB1301461.8A patent/GB201301461D0/en not_active Ceased
-
2014
- 2014-01-28 EP EP14710658.7A patent/EP2948155A1/en not_active Withdrawn
- 2014-01-28 WO PCT/PT2014/000006 patent/WO2014116132A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004041318A1 (en) * | 2002-11-05 | 2004-05-21 | Universiteit Twente | Method for providing shaped biodegradable and elastomeric structures of (co) polymers of 1,3-trimethylene carbonate (tmc), shaped biodegradable and elastomeric structures, and the use of these structures |
Non-Patent Citations (6)
Title |
---|
DANIELA NOGUEIRA ROCHA ET AL: "Poly(Trimethylene Carbonate-co-[epsilon]-Caprolactone) Promotes Axonal Growth", PLOS ONE, vol. 9, no. 2, 27 February 2014 (2014-02-27), pages e88593, XP055112310, DOI: 10.1371/journal.pone.0088593 * |
FABRE T ET AL: "Study of a (trimethylenecarbonate-co-@?-caprolactone) polymer-Part 2: in vitro cytocompatibility analysis and in vivo ED1 cell response of a new nerve guide", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 22, 15 November 2001 (2001-11-15), pages 2951 - 2958, XP004301373, ISSN: 0142-9612, DOI: 10.1016/S0142-9612(01)00012-6 * |
LIETZ M ET AL: "PHYSICAL AND BIOLOGICAL PERFORMANCE OF A NOVEL BLOCK COPOLYMER NERVE GUIDE", BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 93, no. 1, 5 January 2006 (2006-01-05), pages 99 - 109, XP003005189, ISSN: 0006-3592, DOI: 10.1002/BIT.20688 * |
PEGO A P ET AL: "In vivo behavior of poly(1,3-trimethylene carbonate) and copolymers of 1,3-trimethylene carbonate with D,L-lactide or epsilon-caprolactone: Degradation and tissue response", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, WILEY, NEW YORK, NY, US, vol. 67A, no. 3, 1 December 2003 (2003-12-01), pages 1044 - 1054, XP009177425, ISSN: 0021-9304 * |
See also references of EP2948155A1 * |
VLEGGEERT-LANKAMP CARMEN L A M ET AL: "Effect of nerve graft porosity on the refractory period of regenerating nerve fibers - Laboratory investigation", JOURNAL OF NEUROSURGERY, vol. 109, no. 2, August 2008 (2008-08-01), pages 294 - 305, XP009177426, ISSN: 0022-3085 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3006055A1 (en) * | 2014-10-10 | 2016-04-13 | Albert-Ludwigs-Universität Freiburg | Improved biomaterials for neuronal implants and use of said biomaterials in the diagnosis and therapy of neuronal diseases |
WO2016055622A1 (en) * | 2014-10-10 | 2016-04-14 | Albert-Ludwigs-Universität Freiburg | Improved biomaterials for neuronal implants and use of said biomaterials in the diagnosis and therapy of neuronal diseases |
US20170252486A1 (en) * | 2014-10-10 | 2017-09-07 | Albert-Ludwigs-Universitat Freiburg | Biomaterials for neuronal implants and use of said biomaterials in the diagnosis and therapy of neuronal diseases |
US11191874B2 (en) | 2014-10-10 | 2021-12-07 | Albert-Ludwigs-Universitat Freiburg | Biomaterials for neuronal implants and use of said biomaterials in the diagnosis and therapy of neuronal diseases |
US11202852B2 (en) | 2014-10-10 | 2021-12-21 | Albert-Ludwigs-Universitat Freiburg | Biomaterials for neuronal implants and use of said biomaterials in the diagnosis and therapy of neuronal diseases |
Also Published As
Publication number | Publication date |
---|---|
GB201301461D0 (en) | 2013-03-13 |
EP2948155A1 (en) | 2015-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wu et al. | Conductive micropatterned polyurethane films as tissue engineering scaffolds for Schwann cells and PC12 cells | |
US9750851B2 (en) | Implantable medical devices having double walled microspheres | |
Stokols et al. | Freeze-dried agarose scaffolds with uniaxial channels stimulate and guide linear axonal growth following spinal cord injury | |
Rocha et al. | Poly (trimethylene carbonate-co-ε-caprolactone) promotes axonal growth | |
Yang et al. | Nerve conduits based on immobilization of nerve growth factor onto modified chitosan by using genipin as a crosslinking agent | |
Alvarez-Perez et al. | Influence of gelatin cues in PCL electrospun membranes on nerve outgrowth | |
Shayan et al. | Nanopatterned bulk metallic glass-based biomaterials modulate macrophage polarization | |
Vasconcelos et al. | Fibrinogen scaffolds with immunomodulatory properties promote in vivo bone regeneration | |
Woerly et al. | Neural tissue engineering: from polymer to biohybrid organs | |
Lee et al. | Correlating macrophage morphology and cytokine production resulting from biomaterial contact | |
Yu et al. | Guided cell adhesion and outgrowth in peptide-modified channels for neural tissue engineering | |
Pires et al. | Ibuprofen‐loaded poly (trimethylene carbonate‐co‐ε‐caprolactone) electrospun fibres for nerve regeneration | |
Jiang et al. | Enhanced proliferation and differentiation of retinal progenitor cells through a self-healing injectable hydrogel | |
US20100112014A1 (en) | Novel hydrogel compositions and methods of using | |
US11191874B2 (en) | Biomaterials for neuronal implants and use of said biomaterials in the diagnosis and therapy of neuronal diseases | |
Limongi et al. | Delivery of brain-derived neurotrophic factor by 3D biocompatible polymeric scaffolds for neural tissue engineering and neuronal regeneration | |
WO2018013612A1 (en) | Artificial brain tissue | |
US8187823B2 (en) | Modulation of neuroglia-derived BDNF in the treatment and prevention of pain | |
Xu et al. | Alter macrophage adhesion and modulate their response on hydrophobically modified hydrogels | |
Stumpf et al. | Design and evaluation of a biosynthesized cellulose drug releasing duraplasty | |
Wang et al. | Waterborne biodegradable polyurethane 3-dimensional porous scaffold for rat cerebral tissue regeneration | |
EP3953450A1 (en) | A micro physiological model for neuronal and muscular diseases and disorders | |
EP3218021B1 (en) | Compositions for use in a method for the prevention and/or reduction of scarring | |
Altuntas et al. | Local epidermal growth factor delivery using nanopillared chitosan–gelatin films for melanogenesis and wound healing | |
WO2014116132A1 (en) | Biomaterial comprising poly(trimethylene carbonate-co-e-caprolactone) for promoting axonall growth and neuronal regeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14710658 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014710658 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |